Publications
2024
Simulation to optimize the laboratory diagnosis of bacteremia.
Gerada, A., Roberts, G., Howard, A., Reza, N., Velluva, A., Rosato, C., . . . Hope, W. (2024). Simulation to optimize the laboratory diagnosis of bacteremia.. Microbiology spectrum, e0144924. doi:10.1128/spectrum.01449-24
AIgarMIC: a Python package for automated interpretation of agar dilution minimum inhibitory concentration assays
Gerada, A., Harper, N., Howard, A., & Hope, W. (2024). AIgarMIC: a Python package for automated interpretationof agar dilution minimum inhibitory concentration assays. Journal of Open Source Software, 9(101), 6826. doi:10.21105/joss.06826
Bayesian estimation of the prevalence of antimicrobial resistance: a mathematical modelling study.
Howard, A., Green, P. L., Velluva, A., Gerada, A., Hughes, D. M., Brookfield, C., . . . Buchan, I. (2024). Bayesian estimation of the prevalence of antimicrobial resistance: a mathematical modelling study.. The Journal of antimicrobial chemotherapy, dkae230. doi:10.1093/jac/dkae230
<i>Acinetobacter baumannii</i> transformants expressing oxacillinases and metallo-β-lactamases that confer resistance to meropenem: new tools for anti-<i>Acinetobacter</i> drug development and AMR preparedness.
Dubey, V., Farrington, N., Harper, N., Johnson, A., Horner, I., Stevenson, A., . . . Hope, W. (2024). <i>Acinetobacter baumannii</i> transformants expressing oxacillinases and metallo-β-lactamases that confer resistance to meropenem: new tools for anti-<i>Acinetobacter</i> drug development and AMR preparedness.. Antimicrobial agents and chemotherapy, e0022224. doi:10.1128/aac.00222-24
Integration of genomic and pharmacokinetic data to predict clinical outcomes in HIV-associated cryptococcal meningitis.
Stott, K. E., Mohabir, J. T., Bowers, K., Tenor, J. L., Toffaletti, D. L., Unsworth, J., . . . AMBITION Study Group. (2024). Integration of genomic and pharmacokinetic data to predict clinical outcomes in HIV-associated cryptococcal meningitis.. mBio, e0159224. doi:10.1128/mbio.01592-24
Towards pharmacokinetic boosting of phenoxymethylpenicillin (penicillin-V) using probenecid for the treatment of bacterial infections.
Wilson, R. C., Riezk, A., Arkell, P., Ming, D., Armiger, R., Latham, V., . . . Rawson, T. M. (2024). Towards pharmacokinetic boosting of phenoxymethylpenicillin (penicillin-V) using probenecid for the treatment of bacterial infections.. Scientific reports, 14(1), 16762. doi:10.1038/s41598-024-67354-6
Bayesian Calibration to Address the Challenge of Antimicrobial Resistance: A Review
Rosato, C., Green, P. L., Harris, J., Maskell, S., Hope, W., Gerada, A., & Howard, A. (2024). Bayesian Calibration to Address the Challenge of Antimicrobial Resistance: A Review. IEEE Access, 12, 100772-100791. doi:10.1109/access.2024.3427410
Biomarker Driven Antifungal Stewardship (BioDriveAFS) in acute leukaemia-a multi-centre randomised controlled trial to assess clinical and cost effectiveness: a study protocol for a randomised controlled trial.
Flett, L., Abdelatif, R., Baz, S. A., Brady, S., Corbacho, B., Common, K., . . . Barlow, G. (2024). Biomarker Driven Antifungal Stewardship (BioDriveAFS) in acute leukaemia-a multi-centre randomised controlled trial to assess clinical and cost effectiveness: a study protocol for a randomised controlled trial.. Trials, 25(1), 427. doi:10.1186/s13063-024-08272-w
The pathobiology of human fungal infections.
Brown, G. D., Ballou, E. R., Bates, S., Bignell, E. M., Borman, A. M., Brand, A. C., . . . Wilson, D. (2024). The pathobiology of human fungal infections.. Nature reviews. Microbiology. doi:10.1038/s41579-024-01062-w
Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing.
Reza, N., Gerada, A., Stott, K. E., Howard, A., Sharland, M., & Hope, W. (2024). Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing.. Clinical microbiology reviews, 37(2), e0013923. doi:10.1128/cmr.00139-23
A ketogenic diet enhances fluconazole efficacy in murine models of systemic fungal infection.
Palmucci, J. R., Sells, B. E., Giamberardino, C. D., Toffaletti, D. L., Dai, B., Asfaw, Y. G., . . . Perfect, J. R. (2024). A ketogenic diet enhances fluconazole efficacy in murine models of systemic fungal infection.. mBio, 15(5), e0064924. doi:10.1128/mbio.00649-24
System-wide approaches to antimicrobial therapy and antimicrobial resistance in the UK: the AMR-X framework.
AMR-X Collaborators. (2024). System-wide approaches to antimicrobial therapy and antimicrobial resistance in the UK: the AMR-X framework.. The Lancet. Microbe, 5(5), e500-e507. doi:10.1016/s2666-5247(24)00003-x
Determination of minimum inhibitory concentrations using machine-learning-assisted agar dilution.
Gerada, A., Harper, N., Howard, A., Reza, N., & Hope, W. (2024). Determination of minimum inhibitory concentrations using machine-learning-assisted agar dilution.. Microbiology spectrum, e0420923. doi:10.1128/spectrum.04209-23
Molecular pharmacodynamics of meropenem for nosocomial pneumonia caused by <i>Pseudomonas aeruginosa</i>.
Farrington, N., Dubey, V., Johnson, A., Horner, I., Stevenson, A., Unsworth, J., . . . Darlow, C. A. (2024). Molecular pharmacodynamics of meropenem for nosocomial pneumonia caused by <i>Pseudomonas aeruginosa</i>.. mBio, 15(2), e0316523. doi:10.1128/mbio.03165-23
Antimicrobial learning systems: an implementation blueprint for artificial intelligence to tackle antimicrobial resistance.
Howard, A., Aston, S., Gerada, A., Reza, N., Bincalar, J., Mwandumba, H., . . . Buchan, I. (2024). Antimicrobial learning systems: an implementation blueprint for artificial intelligence to tackle antimicrobial resistance.. The Lancet. Digital health, 6(1), e79-e86. doi:10.1016/s2589-7500(23)00221-2
Antimicrobial treatment imprecision: an outcome-based model to close the data-to-action loop.
Howard, A., Reza, N., Aston, S., Woods, B., Gerada, A., Buchan, I., . . . Märtson, A. -G. (2024). Antimicrobial treatment imprecision: an outcome-based model to close the data-to-action loop.. The Lancet. Infectious diseases, 24(1), e47-e58. doi:10.1016/s1473-3099(23)00367-5
2023
Development and application of neonatal physiology-based pharmacokinetic models of amikacin and fosfomycin to assess pharmacodynamic target attainment.
Darlow, C. A., Parrott, N., Peck, R. W., & Hope, W. (2023). Development and application of neonatal physiology-based pharmacokinetic models of amikacin and fosfomycin to assess pharmacodynamic target attainment.. CPT: pharmacometrics & systems pharmacology. doi:10.1002/psp4.13097
Pharmacodynamics of ATI-2307 in a rabbit model of cryptococcal meningoencephalitis.
Giamberardino, C. D., Tenor, J. L., Toffaletti, D. L., Palmucci, J. R., Schell, W., Boua, J. -V. K., . . . Perfect, J. R. (2023). Pharmacodynamics of ATI-2307 in a rabbit model of cryptococcal meningoencephalitis.. Antimicrobial agents and chemotherapy, 67(10), e0081823. doi:10.1128/aac.00818-23
Food and Drug Administration Public Workshop Summary-Development Considerations of Antifungal Drugs to Address Unmet Medical Need
Yasinskaya, Y., Bala, S., Waack, U., Dixon, C., Higgins, K., Moore, J. N., . . . Farley, J. (2023). Food and Drug Administration Public Workshop Summary-Development Considerations of Antifungal Drugs to Address Unmet Medical Need. CLINICAL INFECTIOUS DISEASES, 77(3), 380-387. doi:10.1093/cid/ciad195
Trichosporon inkin and Cutibacterium acnes bioprosthetic aortic valve endocarditis and prosthetic aortic root abscess with multi-focal emboli
Kempson, F., Woolley, S., Coles, Z., Kenawy, A., Muntasser, H., Ghadiri, N., . . . van Aartsen, J. J. (2023). Trichosporon inkin and Cutibacterium acnes bioprosthetic aortic valve endocarditis and prosthetic aortic root abscess with multi-focal emboli. Clinical Infection in Practice, 19, 100233. doi:10.1016/j.clinpr.2023.100233
ChatGPT and antimicrobial advice: the end of the consulting infection doctor?
Howard, A., Hope, W., & Gerada, A. (2023). ChatGPT and antimicrobial advice: the end of the consulting infection doctor?. LANCET INFECTIOUS DISEASES, 23(4), 405. doi:10.1016/S1473-3099(23)00113-5
Population pharmacokinetics and CSF penetration of flucytosine in adults with HIV-associated cryptococcal meningoencephalitis
Stott, K. E., Ahmadu, A., Kajanga, C., Moyo, M., Gondwe, E., Chimang'anga, W., . . . Mwandumba, H. C. (2023). Population pharmacokinetics and CSF penetration of flucytosine in adults with HIV-associated cryptococcal meningoencephalitis. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 78(4), 1015-1022. doi:10.1093/jac/dkad038
Assessment of Antifungal Pharmacodynamics
Howard, A., & Hope, W. (2023). Assessment of Antifungal Pharmacodynamics. JOURNAL OF FUNGI, 9(2). doi:10.3390/jof9020192
2022
Population pharmacokinetics of liposomal amphotericin B in adults with HIV-associated cryptococcal meningoencephalitis
Stott, K. E., Moyo, M., Ahmadu, A., Kajanga, C., Gondwe, E., Chimang'anga, W., . . . Martson, A. -G. (2023). Population pharmacokinetics of liposomal amphotericin B in adults with HIV-associated cryptococcal meningoencephalitis. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 78(1), 276-283. doi:10.1093/jac/dkac389
Efficacy of APX2039 in a Rabbit Model of Cryptococcal Meningitis
Giamberardino, C. D., Schell, W. A., Tenor, J. L., Toffaletti, D. L., Palmucci, J. R., Marius, C., . . . Shaw, K. J. (2022). Efficacy of APX2039 in a Rabbit Model of Cryptococcal Meningitis. MBIO, 13(6). doi:10.1128/mbio.02347-22
Assessment of flomoxef combined with amikacin in a hollow-fibre infection model for the treatment of neonatal sepsis in low- and middle-income healthcare settings
Darlow, C. A., McEntee, L., Johnson, A., Farrington, N., Unsworth, J., Jimenez-Valverde, A., . . . Hope, W. (2022). Assessment of flomoxef combined with amikacin in a hollow-fibre infection model for the treatment of neonatal sepsis in low- and middle-income healthcare settings. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 77(12), 3349-3357. doi:10.1093/jac/dkac323
Addition of probenecid to oral β-lactam antibiotics: a systematic review and meta-analysis
Wilson, R. C., Arkell, P., Riezk, A., Gilchrist, M., Wheeler, G., Hope, W., . . . Rawson, T. M. (2022). Addition of probenecid to oral β-lactam antibiotics: a systematic review and meta-analysis. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 77(9), 2364-2372. doi:10.1093/jac/dkac200
OXA-48-Like β-Lactamases: Global Epidemiology, Treatment Options, and Development Pipeline
Boyd, S. E., Holmes, A., Peck, R., Livermore, D. M., & Hope, W. (2022). OXA-48-Like β-Lactamases: Global Epidemiology, Treatment Options, and Development Pipeline. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 66(8). doi:10.1128/aac.00216-22
CON: Serum biomarker monitoring should not replace primary antifungal chemoprophylaxis in patients with acute leukaemia receiving systemic anti-cancer therapy
Howard, A., & Hope, W. (2022). CON: Serum biomarker monitoring should not replace primary antifungal chemoprophylaxis in patients with acute leukaemia receiving systemic anti-cancer therapy. JAC-ANTIMICROBIAL RESISTANCE, 4(4). doi:10.1093/jacamr/dlac081
Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales (vol 77, pg 711, 2022)
Darlow, C. A., & Hope, W. (2022). Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales (vol 77, pg 711, 2022). JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 77(7), 2049. doi:10.1093/jac/dkac153
Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales-authors' response
Darlow, C. A., & Hope, W. (2022). Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales-authors' response. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 77(7), 2047-2048. doi:10.1093/jac/dkac072
Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance
Darlow, C. A., Farrington, N., Johnson, A., McEntee, L., Unsworth, J., Jimenez-Valverde, A., . . . Hope, W. (2022). Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 77(5), 1334-1343. doi:10.1093/jac/dkac038
Informing Antibiotic Guardianship to Combat Antimicrobial Resistance: The Liverpool Citizens’ Jury on AMR
Hope, W., Amos, J., Atwood, S., Bozentko, K., Lamb, A., Leeming, G., . . . Townsend, A. (n.d.). Informing Antibiotic Guardianship to Combat Antimicrobial Resistance: The Liverpool Citizens’ Jury on AMR. In ESPAUR 2022 (pp. 9). MDPI. doi:10.3390/msf2022015009
Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis
Jarvis, J. N., Lawrence, D. S., Meya, D. B., Kagimu, E., Kasibante, J., Mpoza, E., . . . Harrison, T. S. (2022). Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis. NEW ENGLAND JOURNAL OF MEDICINE, 386(12), 1109-1120. doi:10.1056/NEJMoa2111904
Pharmacodynamics of Meropenem and Tobramycin for Neonatal Meningoencephalitis: Novel Approaches to Facilitate the Development of New Agents to Address the Challenge of Antimicrobial Resistance
Farrington, N., McEntee, L., Johnson, A., Unsworth, J., Darlow, C., Jimenez-Valverde, A., . . . Hope, W. (2022). Pharmacodynamics of Meropenem and Tobramycin for Neonatal Meningoencephalitis: Novel Approaches to Facilitate the Development of New Agents to Address the Challenge of Antimicrobial Resistance. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 66(4). doi:10.1128/aac.02181-21
2021
Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales
Darlow, C. A., & Hope, W. (2021). Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 77(3), 711-718. doi:10.1093/jac/dkab468
Precision Therapy for Invasive Fungal Diseases
Maertson, A. -G., Alffenaar, J. -W. C., Brueggemann, R. J., & Hope, W. (2022). Precision Therapy for Invasive Fungal Diseases. JOURNAL OF FUNGI, 8(1). doi:10.3390/jof8010018
Exploring the Pharmacokinetics of Phenoxymethylpenicillin (Penicillin-V) in Adults: A Healthy Volunteer Study
Rawson, T. M., Wilson, R. C., Moore, L. S. P., Macgowan, A. P., Lovering, A. M., Bayliss, M., . . . Holmes, A. H. (2021). Exploring the Pharmacokinetics of Phenoxymethylpenicillin (Penicillin-V) in Adults: A Healthy Volunteer Study. OPEN FORUM INFECTIOUS DISEASES, 8(12). doi:10.1093/ofid/ofab573
Optimizing antimicrobial use: challenges, advances and opportunities
Rawson, T. M., Wilson, R. C., O'Hare, D., Herrero, P., Kambugu, A., Lamorde, M., . . . Holmes, A. H. (2021). Optimizing antimicrobial use: challenges, advances and opportunities. NATURE REVIEWS MICROBIOLOGY, 19(12), 747-758. doi:10.1038/s41579-021-00578-9
Standard ganciclovir dosing results in slow decline of cytomegalovirus viral loads
Martson, A. -G., Sturkenboom, M. G. G., Knoester, M., van der Werf, T. S., Alffenaar, J. -W. C., Hope, W., & Consortium, G. S. (2021). Standard ganciclovir dosing results in slow decline of cytomegalovirus viral loads. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 77(2), 466-473. doi:10.1093/jac/dkab419
An open label randomized controlled trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis
Nguyen, T. T. N., Nhat, T. H. L., Nguyen, N. V. V., Ninh, T. T. V., Nguyen, T. H. M., Duong, V. A., . . . Day, J. N. (2021). An open label randomized controlled trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis. ELIFE, 10. doi:10.7554/eLife.68929
The praziquantel in preschoolers (PIP) trial: study protocol for a phase II PK/PD-driven randomised controlled trial of praziquantel in children under 4 years of age
Webb, E. L., Edielu, A., Wu, H. W., Kabatereine, N. B., Tukahebwa, E. M., Mubangizi, A., . . . Bustinduy, A. L. (2021). The praziquantel in preschoolers (PIP) trial: study protocol for a phase II PK/PD-driven randomised controlled trial of praziquantel in children under 4 years of age. TRIALS, 22(1). doi:10.1186/s13063-021-05558-1
Cryptococcal meningoencephalitis: time for action
Stott, K. E., Loyse, A., Jarvis, J. N., Alufandika, M., Harrison, T. S., Mwandumba, H. C., . . . Hope, W. (2021). Cryptococcal meningoencephalitis: time for action. LANCET INFECTIOUS DISEASES, 21(9), E259-E271. doi:10.1016/S1473-3099(20)30771-4
Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria
Darlow, C. A., da Costa, R. M. A., Ellis, S., Franceschi, F., Sharland, M., Piddock, L., . . . Hope, W. (2021). Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria. PEDIATRIC DRUGS, 23(5), 465-484. doi:10.1007/s40272-021-00465-z
Application of the hollow fibre infection model (HFIM) in antimicrobial development: a systematic review and recommendations of reporting
Sadouki, Z., McHugh, T. D., Aarnoutse, R., Canseco, J. O., Darlow, C., Hope, W., . . . Kloprogge, F. (2021). Application of the hollow fibre infection model (HFIM) in antimicrobial development: a systematic review and recommendations of reporting. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 76(9), 2252-2259. doi:10.1093/jac/dkab160
Population Pharmacokinetics and Pharmacodynamics of Itraconazole for Disseminated Infection Caused by Talaromyces marneffei.
Stott, K. E., Le, T., Nguyen, T., Whalley, S., Unsworth, J., Ly, V. T., . . . Hope, W. (2021). Population Pharmacokinetics and Pharmacodynamics of Itraconazole for Disseminated Infection Caused by Talaromyces marneffei.. Antimicrobial agents and chemotherapy, 65(11), e0063621. doi:10.1128/aac.00636-21
Optimising antimicrobial use in humans-review of current evidence and an interdisciplinary consensus on key priorities for research
Charani, E., McKee, M., Ahmad, R., Balasegaram, M., Bonaconsa, C., Merrett, G. B., . . . Holmes, A. H. (2021). Optimising antimicrobial use in humans-review of current evidence and an interdisciplinary consensus on key priorities for research. LANCET REGIONAL HEALTH-EUROPE, 7. doi:10.1016/j.lanepe.2021.100161
Amikacin Combined with Fosfomycin for Treatment of Neonatal Sepsis in the Setting of Highly Prevalent Antimicrobial Resistance.
Darlow, C. A., Docobo-Perez, F., Farrington, N., Johnson, A., McEntee, L., Unsworth, J., . . . Hope, W. (2021). Amikacin Combined with Fosfomycin for Treatment of Neonatal Sepsis in the Setting of Highly Prevalent Antimicrobial Resistance.. Antimicrobial Agents and Chemotherapy. doi:10.1128/aac.00293-21
Dosage Individualization of Linezolid: Precision Dosing of Linezolid To Optimize Efficacy and Minimize Toxicity
Luque, S., Hope, W., Sorli, L., Munoz-Bermudez, R., Campillo, N., Barcelo-Vidal, J., . . . Grau, S. (2021). Dosage Individualization of Linezolid: Precision Dosing of Linezolid To Optimize Efficacy and Minimize Toxicity. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 65(6). doi:10.1128/AAC.02490-20
Efficacy and Associated Drug Exposures of Isavuconazole and Fluconazole in an Experimental Model of Coccidioidomycosis.
Kovanda, L. L., Sass, G., Martinez, M., Clemons, K. V., Nazik, H., Kitt, T. M., . . . Stevens, D. A. (2021). Efficacy and Associated Drug Exposures of Isavuconazole and Fluconazole in an Experimental Model of Coccidioidomycosis.. Antimicrobial agents and chemotherapy, 65(6), e02344-e02320. doi:10.1128/aac.02344-20
Population Pharmacokinetics of Piperacillin in Non-Critically Ill Patients with Bacteremia Caused by Enterobacteriaceae
Merino-Bohorquez, V., Docobo-Perez, F., Valiente-Mendez, A., Delgado-Valverde, M., Camean, M., Hope, W. W., . . . Rodriguez-Bano, J. (2021). Population Pharmacokinetics of Piperacillin in Non-Critically Ill Patients with Bacteremia Caused by Enterobacteriaceae. ANTIBIOTICS-BASEL, 10(4). doi:10.3390/antibiotics10040348
Pharmacodynamics of Posaconazole in Experimental Invasive Pulmonary Aspergillosis: Utility of Serum Galactomannan as a Dynamic Endpoint of Antifungal Efficacy
Gastine, S., Hope, W., Hempel, G., Petraitiene, R., Petraitis, V., Mickiene, D., . . . Groll, A. H. (2021). Pharmacodynamics of Posaconazole in Experimental Invasive Pulmonary Aspergillosis: Utility of Serum Galactomannan as a Dynamic Endpoint of Antifungal Efficacy. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 65(2). doi:10.1128/AAC.01574-20
Reply to Asempa et al., "The Ongoing Challenge with NDM-Harboring <i>Enterobacteriaceae</i> in Murine Infection Models"
Das, S., Everett, M., Zalacain, M., & Hope, W. (2021). Reply to Asempa et al., "The Ongoing Challenge with NDM-Harboring <i>Enterobacteriaceae</i> in Murine Infection Models". ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 65(2). doi:10.1128/AAC.02249-20
2020
FDA Public Workshop Summary: Advancing Animal Models for Antibacterial Drug Development
Byrne, J. M., Waack, U., Weinstein, E. A., Joshi, A., Shurland, S. M., Iarikov, D., . . . Farley, J. J. (2021). FDA Public Workshop Summary: Advancing Animal Models for Antibacterial Drug Development. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 65(1). doi:10.1128/AAC.01983-20
Intrapulmonary Pharmacokinetics of Cefepime and Enmetazobactam in Healthy Volunteers: Towards New Treatments for Nosocomial Pneumonia
Das, S., Fitzgerald, R., Ullah, A., Bula, M., Collins, A. M., Mitsi, E., . . . Hope, W. (2021). Intrapulmonary Pharmacokinetics of Cefepime and Enmetazobactam in Healthy Volunteers: Towards New Treatments for Nosocomial Pneumonia. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 65(1). doi:10.1128/AAC.01468-20
Pharmacodynamics of the Novel Metallo-beta-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae
Das, S., Johnson, A., McEntee, L., Farrington, N., Kirby, A., Unsworth, J., . . . Hope, W. (2020). Pharmacodynamics of the Novel Metallo-beta-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 64(11). doi:10.1128/AAC.01076-20
Pharmacodynamics of the Novel Metallo-β-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae.
Das, S., Johnson, A., McEntee, L., Farrington, N., Kirby, A., Unsworth, J., . . . Hope, W. (2020). Pharmacodynamics of the Novel Metallo-β-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae.. Antimicrob Agents Chemother, 64(11). doi:10.1128/AAC.01076-20
Metallo-β-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline
Boyd, S. E., Livermore, D. M., Hooper, D. C., & Hope, W. W. (2020). Metallo-β-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 64(10). doi:10.1128/AAC.00397-20
Population Pharmacokinetics of Praziquantel in Pregnant and Lactating Filipino Women Infected with Schistosoma japonicum
Bustinduy, A. L., Kolamunnage-Dona, R., Mirochnick, M. H., Capparelli, E. V., Tallo, V., Acosta, L. P., . . . Hope, W. W. (2020). Population Pharmacokinetics of Praziquantel in Pregnant and Lactating Filipino Women Infected with Schistosoma japonicum. Antimicrobial Agents and Chemotherapy, 64(9). doi:10.1128/AAC.00566-20
How to design a study to evaluate therapeutic drug monitoring in infectious diseases?
Martson, A. -G., Sturkenboom, M. G. G., Stojanova, J., Cattaneo, D., Hope, W., Marriott, D., . . . Alffenaar, J. -W. C. (2020). How to design a study to evaluate therapeutic drug monitoring in infectious diseases?. Clinical Microbiology and Infection, 26(8), 1008-1016. doi:10.1016/j.cmi.2020.03.008
Methodological features of clinical pharmacokinetic-pharmacodynamic studies of antibacterials and antifungals: a systematic review
McAleenan, A., Ambrose, P. G., Bhavnani, S. M., Drusano, G. L., Hope, W. W., Mouton, J. W., . . . MacGowan, A. P. (2020). Methodological features of clinical pharmacokinetic-pharmacodynamic studies of antibacterials and antifungals: a systematic review. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(6), 1374-1389. doi:10.1093/jac/dkaa005
Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum-β-Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing <i>Klebsiella pneumoniae</i>
Johnson, A., McEntee, L., Farrington, N., Kolamunnage-Dona, R., Franzoni, S., Vezzelli, A., . . . Hope, W. (2020). Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum-β-Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing <i>Klebsiella pneumoniae</i>. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 64(6). doi:10.1128/AAC.00180-20
An optimised dosing regimen versus a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to Gram-positive microorganisms in neonates and infants aged less than 90 days (NeoVanc): study protocol for a randomised controlled trial
Hill, L. F., Turner, M. A., Lutsar, I., Heath, P. T., Hardy, P., Linsell, L., . . . Sharland, M. (2020). An optimised dosing regimen versus a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to Gram-positive microorganisms in neonates and infants aged less than 90 days (NeoVanc): study protocol for a randomised controlled trial. TRIALS, 21(1). doi:10.1186/s13063-020-4184-8
Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial
Benitez-Cano, A., Luque, S., Sorli, L., Carazo, J., Ramos, I., Campillo, N., . . . Grau, S. (2020). Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial. CRITICAL CARE, 24(1). doi:10.1186/s13054-020-2763-4
Setting Our Sights on Infectious Diseases
De Rycker, M., Horn, D., Aldridge, B., Amewu, R. K., Barry, C. E. I. I. I., Buckner, F. S., . . . Gilbert, I. H. (2020). Setting Our Sights on Infectious Diseases. ACS INFECTIOUS DISEASES, 6(1), 3-13. doi:10.1021/acsinfecdis.9b00371
2019
Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance.
Hope, W., Stone, N. R. H., Johnson, A., McEntee, L., Farrington, N., Santoro-Castelazo, A., . . . Bicanic, T. (2019). Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance.. mBio, 10(6). doi:10.1128/mbio.02575-19
Amphotericin B Penetrates into the Central Nervous System through Focal Disruption of the Blood-Brain Barrier in Experimental Hematogenous <i>Candida</i> Meningoencephalitis
Petraitis, V., Petraitiene, R., Valdez, J. M., Pyrgos, V., Lizak, M. J., Klaunberg, B. A., . . . Walsh, T. J. (2019). Amphotericin B Penetrates into the Central Nervous System through Focal Disruption of the Blood-Brain Barrier in Experimental Hematogenous <i>Candida</i> Meningoencephalitis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63(12). doi:10.1128/AAC.01626-19
Twenty-four hour pharmacokinetic relationships for intravenous vancomycin and novel urinary biomarkers of acute kidney injury in a rat model
Avedissian, S. N., Pais, G. M., O'Donnell, J. N., Lodise, T. P., Liu, J., Prozialeck, W. C., . . . Scheetz, M. H. (2019). Twenty-four hour pharmacokinetic relationships for intravenous vancomycin and novel urinary biomarkers of acute kidney injury in a rat model. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 74(8), 2326-2334. doi:10.1093/jac/dkz167
Population pharmacokinetics of continuous-infusion ceftazidime in febrile neutropenic children undergoing HSCT: implications for target attainment for empirical treatment against <i>Pseudomonas aeruginosa</i>
Cojutti, P. G., Maximova, N., Schillani, G., Hope, W., & Pea, F. (2019). Population pharmacokinetics of continuous-infusion ceftazidime in febrile neutropenic children undergoing HSCT: implications for target attainment for empirical treatment against <i>Pseudomonas aeruginosa</i>. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 74(6), 1648-1655. doi:10.1093/jac/dkz065
Generating robust and informative nonclinical in vitro and in vivo bacterial infection model efficacy data to support translation to humans.
Bulitta, J. B., Hope, W. W., Eakin, A. E., Guina, T., Tam, V. H., Louie, A., . . . Hoover, J. L. (2019). Generating Robust and Informative Nonclinical <i>In Vitro</i> and <i>In Vivo</i> Bacterial Infection Model Efficacy Data To Support Translation to Humans. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63(5). doi:10.1128/AAC.02307-18
Population Pharmacokinetic Modeling of VL-2397, A Novel Systemic Antifungal Agent: Analysis of a Single and Multiple Ascending Dose Study in Healthy Subjects.
Kovanda, L. L., Sullivan, S. M., Smith, L. R., Desai, A. V., Bonate, P. L., & Hope, W. W. (2019). Population Pharmacokinetic Modeling of VL-2397, A Novel Systemic Antifungal Agent: Analysis of a Single and Multiple Ascending Dose Study in Healthy Subjects.. Antimicrobial agents and chemotherapy. doi:10.1128/aac.00163-19
CSF penetration of vancomycin in critical care patients with proven or suspected ventriculitis: a prospective observational study
Blassmann, U., Hope, W., Roehr, A. C., Frey, O. R., Vetter-Kerkhoff, C., Thon, N., . . . Huge, V. (2019). CSF penetration of vancomycin in critical care patients with proven or suspected ventriculitis: a prospective observational study. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 74(4), 991-996. doi:10.1093/jac/dky543
Dynamic ploidy changes drive fluconazole resistance in human cryptococcal meningitis
Stone, N. R. H., Rhodes, J., Fisher, M. C., Mfinanga, S., Kivuyo, S., Rugemalila, J., . . . Bicanic, T. (2019). Dynamic ploidy changes drive fluconazole resistance in human cryptococcal meningitis. JOURNAL OF CLINICAL INVESTIGATION, 129(3), 999-1014. doi:10.1172/JCI124516
Population Pharmacodynamics of Amphotericin B Deoxycholate for Disseminated Infection Caused by Talaromyces marneffei
Le, T., Ly, V. T., Thu, N. T. M., Nguyen, A., Thanh, N. T., Vinh Chau, N. V., . . . Hope, W. (2019). Population Pharmacodynamics of Amphotericin B Deoxycholate for Disseminated Infection Caused by Talaromyces marneffei. Antimicrobial Agents and Chemotherapy, 63(2). doi:10.1128/aac.01739-18
Software for Dosage Individualization of Voriconazole: a Prospective Clinical Study.
Hope, W., Johnstone, G., Cicconi, S., Felton, T., Goodwin, J., Whalley, S., . . . Neely, M. (2019). Software for Dosage Individualization of Voriconazole: a Prospective Clinical Study.. Antimicrobial agents and chemotherapy. doi:10.1128/aac.02353-18
Short Course High-dose Liposomal Amphotericin B for HIV-associated Cryptococcal Meningitis: A phase-II Randomized Controlled Trial.
Jarvis, J. N., Leeme, T. B., Molefi, M., Chofle, A. A., Bidwell, G., Tsholo, K., . . . Harrison, T. S. (2019). Short-course High-dose Liposomal Amphotericin B for Human Immunodeficiency Virus-associated Cryptococcal Meningitis: A Phase 2 Randomized Controlled Trial. CLINICAL INFECTIOUS DISEASES, 68(3), 393-401. doi:10.1093/cid/ciy515
AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial (vol 19, 649, 2018)
Lawrence, D. S., Youssouf, N., Molloy, S. F., Alanio, A., Alufandika, M., Boulware, D. R., . . . Jarvis, J. N. (2019). AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial (vol 19, 649, 2018). TRIALS, 20. doi:10.1186/s13063-018-3155-9
A randomized open label trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis.
Ngan, N. T. T., Mai, N. T. H., Tung, N. L. N., Lan, N. P. H., Tai, L. T. H., Phu, N. H., . . . Day, J. (2019). A randomized open label trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis.. Wellcome open research, 4, 8. doi:10.12688/wellcomeopenres.15010.1
Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials
Andes, D. R., Ghannoum, M. A., Mukherjee, P. K., Kovanda, L. L., Lu, Q., Jones, M. E., . . . Hope, W. W. (2019). Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63(1). doi:10.1128/AAC.01634-18
POPULATION PHARMACOKINETICS OF ANIDULAFUNGIN IN CRITICALLY ILL PATIENTS.
Luque, S., Hope, W., Campillo, N., Munoz-Bermudez, R., Sorli, L., Barcelo-Vidal, J., . . . Grau, S. (2019). Population Pharmacokinetics of Anidulafungin in Critically III Patients. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63(7). doi:10.1128/AAC.00378-19
Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis
Kovanda, L. L., Giamberardino, C., McEntee, L., Toffaletti, D. L., Franke, K. S., Bartuska, A., . . . Perfect, J. R. (2019). Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63(9). doi:10.1128/AAC.00546-19
Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multi-Drug Resistant Gram-Negative Infections.
McEntee, L., Johnson, A., Farrington, N., Unsworth, J., Dane, A., Jain, A., . . . Hope, W. (2019). Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63(8). doi:10.1128/AAC.00603-19
2018
Population Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal Meningitis (vol 62, e02526-17, 2018)
Stott, K. E., Beardsley, J., Whalley, S., Kibengo, F. M., Nguyen, T. H. M., Nguyen, L. N. T., . . . Day, J. (2018). Population Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal Meningitis (vol 62, e02526-17, 2018). ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(12). doi:10.1128/AAC.02249-18
Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis (vol 62, e00885-18, 2018)
Stott, K. E., Beardsley, J., Kolamunnage-Dona, R., Castelazo, A. S., Kibengo, F. M., Nguyen, T. H. M., . . . Hope, W. (2018). Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis (vol 62, e00885-18, 2018). ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(12). doi:10.1128/AAC.02254-18
AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial
Lawrence, D. S., Youssouf, N., Molloy, S. L. F., Alanio, A., Alufandika, M., Boulware, D. R., . . . Jarvis, J. N. (2018). AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial. TRIALS, 19. doi:10.1186/s13063-018-3026-4
Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with haematological malignancies
Cojutti, P. G., Candoni, A., Lazzarotto, D., Rabassi, N., Fanin, R., Hope, W., & Pea, F. (2018). Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with haematological malignancies. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 84(11), 2544-2550. doi:10.1111/bcp.13707
Population pharmacokinetics and pharmacodynamics of fosfomycin in non-critically ill patients with bacteremic urinary infection caused by multidrug-resistant <i>Escherichia coli</i>
Merino-Bohorquez, V., Docobo-Perez, F., Sojo, J., Morales, I., Lupion, C., Martin, D., . . . Rodriguez-Bano, J. (2018). Population pharmacokinetics and pharmacodynamics of fosfomycin in non-critically ill patients with bacteremic urinary infection caused by multidrug-resistant <i>Escherichia coli</i>. CLINICAL MICROBIOLOGY AND INFECTION, 24(11), 1177-1183. doi:10.1016/j.cmi.2018.02.005
Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with <i>Candida albicans</i> and non<i>-albicans</i> spp.
Cojutti, P. G., Lugano, M., Righi, E., Della Rocca, G., Bassetti, M., Hope, W., & Pea, F. (2018). Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with <i>Candida albicans</i> and non<i>-albicans</i> spp.. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 74(11), 1449-1459. doi:10.1007/s00228-018-2526-1
A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants with Invasive Candidiasis.
Benjamin, D. K. J., Kaufman, D. A., Hope, W. W., Smith, P. B., Arrieta, A., Manzoni, P., . . . Walsh, T. J. (2018). A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 37(10), 992-998. doi:10.1097/INF.0000000000001996
Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis
Stott, K. E., Beardsley, J., Kolamunnage-Dona, R., Santoyo Castelazo, A., Kibengo, F. M., Mai, N. T. H., . . . Hope, W. (2018). Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis. Antimicrobial Agents and Chemotherapy, 62(9). doi:10.1128/aac.00885-18
Higher than standard meropenem and linezolid dosages needed for appropriate treatment of an intracerebral hemorrhage patient with augmented renal clearance
Cojutti, P. G., Barbarino, C., De Monte, A., Hope, W., & Pea, F. (2018). Higher than standard meropenem and linezolid dosages needed for appropriate treatment of an intracerebral hemorrhage patient with augmented renal clearance. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 74(8), 1091-1092. doi:10.1007/s00228-018-2465-x
Pharmacokinetics-pharmacodynamics of antifungal agents in the central nervous system
Stott, K. E., & Hope, W. (2018). Pharmacokinetics-pharmacodynamics of antifungal agents in the central nervous system. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 14(8), 803-815. doi:10.1080/17425255.2018.1492551
Population Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal Meningitis
Stott, K. E., Beardsley, J., Whalley, S., Kibengo, F. M., Mai, N. T. H., Tung, N. L. N., . . . Day, J. (2018). Population Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal Meningitis. Antimicrobial agents and chemotherapy, 62(7). doi:10.1128/aac.02526-17
Exploring the Use of C-Reactive Protein to Estimate the Pharmacodynamics of Vancomycin.
Rawson, T. M., Charani, E., Moore, L. S. P., Gilchrist, M., Georgiou, P., Hope, W., & Holmes, A. H. (2018). Exploring the Use of C-Reactive Protein to Estimate the Pharmacodynamics of Vancomycin. THERAPEUTIC DRUG MONITORING, 40(3), 315-321. doi:10.1097/FTD.0000000000000507
Comparison of piperacillin exposure in the lungs of critically ill patients and healthy volunteers
Felton, T. W., Ogungbenro, K., Boselli, E., Hope, W. W., & Rodvold, K. A. (2018). Comparison of piperacillin exposure in the lungs of critically ill patients and healthy volunteers. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 73(5), 1340-1347. doi:10.1093/jac/dkx541
Pharmacodynamics of Voriconazole for Invasive Pulmonary Scedosporiosis.
Box, H., Negri, C., Livermore, J., Whalley, S., Johnson, A., McEntee, L., . . . Hope, W. (2018). Pharmacodynamics of Voriconazole for Invasive Pulmonary Scedosporiosis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(5). doi:10.1128/AAC.02516-17
Delivering precision antimicrobial therapy through closed-loop control systems.
Rawson, T. M., O'Hare, D., Herrero, P., Sharma, S., Moore, L. S. P., de Barra, E., . . . Holmes, A. H. (2018). Delivering precision antimicrobial therapy through closed-loop control systems. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 73(4), 835-843. doi:10.1093/jac/dkx458
Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by Aspergillus flavus.
Negri, C. E., Johnson, A., McEntee, L., Box, H., Whalley, S., Schwartz, J. A., . . . Hope, W. W. (2018). Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by Aspergillus flavus.. The Journal of infectious diseases, 217(7), 1118-1127. doi:10.1093/infdis/jix479
Repurposing and Reformulation of the Antiparasitic Agent Flubendazole for Treatment of Cryptococcal Meningoencephalitis, a Neglected Fungal Disease
Nixon, G. L., McEntee, L., Johnson, A., Farrington, N., Whalley, S., Livermore, J., . . . Hope, W. (2018). Repurposing and Reformulation of the Antiparasitic Agent Flubendazole for Treatment of Cryptococcal Meningoencephalitis, a Neglected Fungal Disease. Antimicrobial Agents and Chemotherapy, 62(4), e01909-e01917. doi:10.1128/aac.01909-17
Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a <i>post hoc</i> analysis of the SECURE trial
Kontoyiannis, D. P., Selleslag, D., Mullane, K., Cornely, O. A., Hope, W., Lortholary, O., . . . Patterson, T. F. (2018). Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a <i>post hoc</i> analysis of the SECURE trial. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 73(3), 757-763. doi:10.1093/jac/dkx423
Suboptimal Exposure to Anti-TB Drugs in a TBM/HIV plus Population Is Not Related to Antiretroviral Therapy
Torok, M. E., Aljayyoussi, G., Waterhouse, D., Chau, T. T. H., Mai, N. T. H., Phu, N. H., . . . Ward, S. A. (2018). Suboptimal Exposure to Anti-TB Drugs in a TBM/HIV plus Population Is Not Related to Antiretroviral Therapy. CLINICAL PHARMACOLOGY & THERAPEUTICS, 103(3), 449-457. doi:10.1002/cpt.646
Antifungal Dosing Considerations for Term and Preterm Infants
Lestner, J., & Hope, W. (2019). Antifungal Dosing Considerations for Term and Preterm Infants. In Infectious Disease and Pharmacology (pp. 185-191). Elsevier. doi:10.1016/b978-0-323-54391-0.00015-1
2017
Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi.
Desai, A. V., Kovanda, L. L., Hope, W. W., Andes, D., Mouton, J. W., Kowalski, D. L., . . . Bonate, P. L. (2017). Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(12). doi:10.1128/AAC.01034-17
Pharmacodynamics of teicoplanin against MRSA
Ramos-Martin, V., Johnson, A., McEntee, L., Farrington, N., Padmore, K., Cojutti, P., . . . Hope, W. W. (2017). Pharmacodynamics of teicoplanin against MRSA. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72(12), 3382-3389. doi:10.1093/jac/dkx289
Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats
Schmitt-Hoffmann, A. -H., Kato, K., Townsend, R., Potchoiba, M. J., Hope, W. W., Andes, D., . . . Schneidkraut, M. J. (2017). Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(12). doi:10.1128/AAC.01292-17
Considerations for effect site pharmacokinetics to estimate drug exposure: concentrations of antibiotics in the lung
Rodvold, K. A., Hope, W. W., & Boyd, S. E. (2017). Considerations for effect site pharmacokinetics to estimate drug exposure: concentrations of antibiotics in the lung. CURRENT OPINION IN PHARMACOLOGY, 36, 114-123. doi:10.1016/j.coph.2017.09.019
Combination Therapy with Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary Aspergillosis.
Petraitis, V., Petraitiene, R., McCarthy, M. W., Kovanda, L. L., Zaw, M. H., Hussain, K., . . . Walsh, T. J. (2017). Combination Therapy with Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary Aspergillosis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(9). doi:10.1128/AAC.00305-17
Combination therapy for carbapenemase-producing Enterobacteriaceae: INCREMENT-al effect on resistance remains unclear
Boyd, S. E., Moore, L. S. P., Rawson, T. M., Hope, W. W., & Holmes, A. H. (2017). Combination therapy for carbapenemase-producing Enterobacteriaceae: INCREMENT-al effect on resistance remains unclear. LANCET INFECTIOUS DISEASES, 17(9), 899-+. doi:10.1016/S1473-3099(17)30450-4
Pharmacodynamics of the Orotomides against Aspergillus fumigatus: New Opportunities for Treatment of Multidrug-Resistant Fungal Disease.
Hope, W. W., McEntee, L., Livermore, J., Whalley, S., Johnson, A., Farrington, N., . . . Rex, J. H. (n.d.). Pharmacodynamics of the Orotomides against Aspergillus fumigatus: New Opportunities for Treatment of Multidrug-Resistant Fungal Disease.. mBio, 8(4). doi:10.1128/mbio.01157-17
A systematic review of clinical decision support systems for antimicrobial management: are we failing to investigate these interventions appropriately?
Rawson, T. M., Moore, L. S. P., Hernandez, B., Charani, E., Castro-Sanchez, E., Herrero, P., . . . Holmes, A. H. (2017). A systematic review of clinical decision support systems for antimicrobial management: are we failing to investigate these interventions appropriately?. CLINICAL MICROBIOLOGY AND INFECTION, 23(8), 524-532. doi:10.1016/j.cmi.2017.02.028
Population pharmacokinetics and dosing considerations for the use of daptomycin in adult patients with haematological malignancies.
Cojutti, P. G., Candoni, A., Ramos-Martin, V., lazzarotto, D., Zannier, M. E., Fanin, R., . . . Pea, F. (2017). Population pharmacokinetics and dosing considerations for the use of daptomycin in adult patients with haematological malignancies. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72(8), 2342-2350. doi:10.1093/jac/dkx140
Endpoint Assessment in Rabbit Models of Invasive Pulmonary Aspergillosis and Mucormycosis.
Petraitis, V., Petraitiene, R., Hope, W. W., & Walsh, T. J. (2017). Endpoint Assessment in Rabbit Models of Invasive Pulmonary Aspergillosis and Mucormycosis.. Methods in molecular biology (Clifton, N.J.), 1625, 259-277. doi:10.1007/978-1-4939-7104-6_18
Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis.
Lestner, J., McEntee, L., Johnson, A., Livermore, J., Whalley, S., Schwartz, J., . . . Hope, W. (2017). Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis.. Antimicrobial agents and chemotherapy, 61(06), 11 pages. doi:10.1128/aac.00090-17
Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole
Kovanda, L. L., Marty, F. M., Maertens, J., Desai, A. V., Lademacher, C., Engelhardt, M., . . . Hope, W. W. (2017). Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(6). doi:10.1128/AAC.00101-17
PHARMACOKINETICS OF ORALLY ADMINISTERED VORICONAZOLE IN AFRICAN PENGUINS (SPHENISCUS DEMERSUS) AFTER SINGLE AND MULTIPLE DOSES.
Hyatt, M. W., Wiederhold, N. P., Hope, W. W., & Stott, K. E. (2017). PHARMACOKINETICS OF ORALLY ADMINISTERED VORICONAZOLE IN AFRICAN PENGUINS (<i>SPHENISCUS DEMERSUS</i>) AFTER SINGLE AND MULTIPLE DOSES. JOURNAL OF ZOO AND WILDLIFE MEDICINE, 48(2), 352-362. doi:10.1638/2016-0160R2.1
Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response
Kovanda, L. L., Kolamunnage-Dona, R., Neely, M., Maertens, J., Misun, L., & Hope, W. (2017). Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response. Clinical Infectious Diseases, 64(11), 1557-1563. doi:10.1093/cid/cix198
The Potential Role of Fosfomycin in Neonatal Sepsis Caused by Multidrug-Resistant Bacteria.
Li, G., Standing, J. F., Bielicki, J., Hope, W., van den Anker, J., Heath, P. T., & Sharland, M. (2017). The Potential Role of Fosfomycin in Neonatal Sepsis Caused by Multidrug-Resistant Bacteria. DRUGS, 77(9), 941-950. doi:10.1007/s40265-017-0745-x
Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis
Kovanda, L. L., Desai, A. V., & Hope, W. W. (2017). Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 44(2), 143-151. doi:10.1007/s10928-017-9509-1
Population Pharmacokinetics and Pharmacodynamics of Levofloxacin in Acutely Hospitalized Older Patients with Various Degrees of Renal Function
Cojutti, P. G., Ramos-Martin, V., Schiavon, I., Rossi, P., Baraldo, M., Hope, W., & Pea, F. (2017). Population Pharmacokinetics and Pharmacodynamics of Levofloxacin in Acutely Hospitalized Older Patients with Various Degrees of Renal Function. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(3). doi:10.1128/AAC.02134-16
Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations.
Stott, K. E., & Hope, W. W. (2017). Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72, I12-I18. doi:10.1093/jac/dkx029
Vancomycin therapy in secondary care; investigating factors that impact therapeutic target attainment
Rawson, T. M., Charani, E., Moore, L. S. P., Herrero, P., Baik, J. S., Philip, A., . . . Holmes, A. H. (2017). Vancomycin therapy in secondary care; investigating factors that impact therapeutic target attainment. JOURNAL OF INFECTION, 74(3), 320-324. doi:10.1016/j.jinf.2016.12.011
Safety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients
Seibel, N. L., Shad, A. T., Bekersky, I., Groll, A. H., Gonzalez, C., Wood, L. V., . . . Walsh, T. J. (2017). Safety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(2). doi:10.1128/AAC.01477-16
Haloprogin
Ramos-Martín, V., & Hope, W. (2017). Haloprogin. In Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition (pp. 2933-2935). doi:10.1201/9781315152110
Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of <i>Pseudomonas aeruginosa</i> and <i>Klebsiella pneumoniae</i> in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy
Sime, F. B., Johnson, A., Whalley, S., Santoyo-Castelazo, A., Montgomery, A. B., Walters, K. A., . . . Roberts, J. A. (2017). Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of <i>Pseudomonas aeruginosa</i> and <i>Klebsiella pneumoniae</i> in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(1). doi:10.1128/AAC.01763-16
Tools for the Individualized Therapy of Teicoplanin for Neonates and Children.
Ramos-Martin, V., Neely, M. N., Padmore, K., Peak, M., Beresford, M. W., Turner, M. A., . . . Hope, W. W. (2017). Tools for the Individualized Therapy of Teicoplanin for Neonates and Children. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(10). doi:10.1128/AAC.00707-17
2016
Population Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Children
Lestner, J. M., Groll, A. H., Aljayyoussi, G., Seibel, N. L., Shad, A., Gonzalez, C., . . . Hope, W. W. (2016). Population Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Children. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(12), 7340-7346. doi:10.1128/AAC.01427-16
F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase
Oliver, J. D., Sibley, G. E. M., Beckmann, N., Dobb, K. S., Slater, M. J., McEntee, L., . . . Birch, M. (2016). F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 113(45), 12809-12814. doi:10.1073/pnas.1608304113
Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality
Hope, W., Drusano, G. L., & Rex, J. H. (2016). Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(11), 3008-3019. doi:10.1093/jac/dkw298
Population pharmacokinetics and pharmacodynamics of teicoplanin in neonates: making better use of C-reactive protein to deliver individualized therapy.
Ramos-Martín, V., Neely, M. N., McGowan, P., Siner, S., Padmore, K., Peak, M., . . . Hope, W. W. (2016). Population pharmacokinetics and pharmacodynamics of teicoplanin in neonates: making better use of C-reactive protein to deliver individualized therapy.. The Journal of antimicrobial chemotherapy, 71(11), 3168-3178. doi:10.1093/jac/dkw295
Cerebrospinal fluid penetration of meropenem in neurocritical care patients with proven or suspected ventriculitis: a prospective observational study
Blassmann, U., Roehr, A. C., Frey, O. R., Vetter-Kerkhoff, C., Thon, N., Hope, W., . . . Huge, V. (2016). Cerebrospinal fluid penetration of meropenem in neurocritical care patients with proven or suspected ventriculitis: a prospective observational study. CRITICAL CARE, 20. doi:10.1186/s13054-016-1523-y
Population Pharmacokinetics and Pharmacodynamics of Praziquantel in Ugandan Children with Intestinal Schistosomiasis: Higher Dosages Are Required for Maximal Efficacy
Bustinduy, A. L., Waterhouse, D., de Sousa-Figueiredo, J. C., Roberts, S. A., Atuhaire, A., Van Dam, G. J., . . . Stothard, J. R. (2016). Population Pharmacokinetics and Pharmacodynamics of Praziquantel in Ugandan Children with Intestinal Schistosomiasis: Higher Dosages Are Required for Maximal Efficacy. mBio, 7(4). doi:10.1128/mBio.00227-16
Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study)
Kovanda, L. L., Desai, A. V., Lu, Q., Townsend, R. W., Akhtar, S., Bonate, P., & Hope, W. W. (2016). Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study). ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(8), 4568-4576. doi:10.1128/AAC.00514-16
Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial
Hope, W. W., Walsh, T. J., Goodwin, J., Peloquin, C. A., Howard, A., Kurtzberg, J., . . . Wingard, J. R. (2016). Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(8), 2234-2240. doi:10.1093/jac/dkw127
Isavuconazonium sulfate: A new agent for the treatment of invasive aspergillosis and invasive mucormycosis
Kovanda, L. L., Maher, R., & Hope, W. W. (2016). Isavuconazonium sulfate: A new agent for the treatment of invasive aspergillosis and invasive mucormycosis. Expert Review of Clinical Pharmacology, 9(7), 887-897. doi:10.1080/17512433.2016.1185361
Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints
Kovanda, L. L., Petraitiene, R., Petraitis, V., Walsh, T. J., Desai, A., Bonate, P., & Hope, W. W. (2016). Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(7), 1885-1891. doi:10.1093/jac/dkw098
Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis
Petraitis, V., Petraitiene, R., Moradi, P. W., Strauss, G. E., Katragkou, A., Kovanda, L. L., . . . Walsh, T. J. (2016). Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(5), 2718-2726. doi:10.1128/AAC.02665-15
Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy
Huurneman, L. J., Neely, M., Veringa, A., Docobo Perez, F., Ramos-Martin, V., Tissing, W. J., . . . Hope, W. (2016). Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(4), 2336-2342. doi:10.1128/AAC.03023-15
Pharmacodynamics of vancomycin for CoNS infection: experimental basis for optimal use of vancomycin in neonates
Ramos-Martin, V., Johnson, A., Livermore, J., McEntee, L., Goodwin, J., Whalley, S., . . . Hope, W. W. (2016). Pharmacodynamics of vancomycin for CoNS infection: experimental basis for optimal use of vancomycin in neonates. Journal of Antimicrobial Chemotherapy, 71(4), 992-1002. doi:10.1093/jac/dkv451
Liposomal Amphotericin B (AmBisome<SUP>®</SUP>): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions
Stone, N. R. H., Bicanic, T., Salim, R., & Hope, W. (2016). Liposomal Amphotericin B (AmBisome<SUP>®</SUP>): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions. DRUGS, 76(4), 485-500. doi:10.1007/s40265-016-0538-7
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial
Maertens, J. A., Raad, I. I., Marr, K. A., Patterson, T. F., Kontoyiannis, D. P., Cornely, O. A., . . . Ullmann, A. J. (2016). Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. The Lancet, 387(10020), 760-769. doi:10.1016/S0140-6736(15)01159-9
Antifungal Pharmacokinetics and Pharmacodynamics
Hope, W., & Andes, D. R. (2016). Antifungal Pharmacokinetics and Pharmacodynamics. In Methods in Pharmacology and Toxicology (pp. 369-383). Springer New York. doi:10.1007/978-1-4939-3323-5_15
Pharmacodynamics of Isavuconazole in a Dynamic <i>In Vitro</i> Model of Invasive Pulmonary Aspergillosis
Box, H., Livermore, J., Johnson, A., McEntee, L., Felton, T. W., Whalley, S., . . . Hope, W. W. (2016). Pharmacodynamics of Isavuconazole in a Dynamic <i>In Vitro</i> Model of Invasive Pulmonary Aspergillosis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(1), 278-287. doi:10.1128/AAC.01364-15
2015
Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1
Drusano, G. L., Louie, A., MacGowan, A., & Hope, W. (2016). Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(3), 1183-1193. doi:10.1128/AAC.02177-15
Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 2
Drusano, G. L., Hope, W., MacGowan, A., & Louie, A. (2016). Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 2. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(3), 1194-1201. doi:10.1128/AAC.02231-15
Intermittent Dosing of Micafungin Is Effective for Treatment of Experimental Disseminated Candidiasis in Persistently Neutropenic Rabbits
Petraitiene, R., Petraitis, V., Hope, W. W., & Walsh, T. J. (2015). Intermittent Dosing of Micafungin Is Effective for Treatment of Experimental Disseminated Candidiasis in Persistently Neutropenic Rabbits. CLINICAL INFECTIOUS DISEASES, 61, S643-S651. doi:10.1093/cid/civ817
Therapeutic drug monitoring of the β-lactam antibiotics: what is the evidence and which patients should we be using it for?
Huttner, A., Harbarth, S., Hope, W. W., Lipman, J., & Roberts, J. A. (2015). Therapeutic drug monitoring of the β-lactam antibiotics: what is the evidence and which patients should we be using it for?. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(12), 3178-3183. doi:10.1093/jac/dkv201
Clinical pharmacology of antifungal agents in pediatrics: children are not small adults
Ramos-Martin, V., O'Connor, O., & Hope, W. (2015). Clinical pharmacology of antifungal agents in pediatrics: children are not small adults. CURRENT OPINION IN PHARMACOLOGY, 24, 128-134. doi:10.1016/j.coph.2015.08.009
Linezolid underexposure in a patient co-treated with venlafaxine
Cojutti, P., Crapis, M., Bassetti, M., Hope, W., & Pea, F. (2015). Linezolid underexposure in a patient co-treated with venlafaxine. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 71(10), 1285-1286. doi:10.1007/s00228-015-1922-z
Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis
Grau, S., Luque, S., Campillo, N., Samso, E., Rodriguez, U., Garcia-Bernedo, C. A., . . . Roberts, J. A. (2015). Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(10), 2854-2861. doi:10.1093/jac/dkv173
Pharmacodynamics of Fosfomycin: Insights into Clinical Use for Antimicrobial Resistance
Docobo-Perez, F., Drusano, G. L., Johnson, A., Goodwin, J., Whalley, S., Ramos-Martin, V., . . . Hope, W. W. (2015). Pharmacodynamics of Fosfomycin: Insights into Clinical Use for Antimicrobial Resistance. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 59(9), 5602-5610. doi:10.1128/AAC.00752-15
AMBITION-<i>cm</i>: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial
Molefi, M., Chofle, A. A., Molloy, S. F., Kalluvya, S., Changalucha, J. M., Cainelli, F., . . . Jarvis, J. N. (2015). AMBITION-<i>cm</i>: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial. TRIALS, 16. doi:10.1186/s13063-015-0799-6
Achieving target voriconazole concentrations more accurately in children and adolescents
Neely, M., Margol, A., Fu, X., van Guilder, M., Bayard, D., Schumitzky, A., . . . Hope, W. (2015). Achieving target voriconazole concentrations more accurately in children and adolescents. Antimicrobial Agents and Chemotherapy, 59(6), 3090-3097. doi:10.1128/AAC.00032-15
Pharmacodynamics of Amphotericin B Deoxycholate, Amphotericin B Lipid Complex, and Liposomal Amphotericin B against <i>Aspergillus fumigatus</i>
Al-Nakeeb, Z., Petraitis, V., Goodwin, J., Petraitiene, R., Walsh, T. J., & Hope, W. W. (2015). Pharmacodynamics of Amphotericin B Deoxycholate, Amphotericin B Lipid Complex, and Liposomal Amphotericin B against <i>Aspergillus fumigatus</i>. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 59(5), 2735-2745. doi:10.1128/AAC.04723-14
Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients
Roberts, J. A., Udy, A. A., Jarrett, P., Wallis, S. C., Hope, W. W., Sharma, R., . . . Lipman, J. (2015). Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(5), 1495-1502. doi:10.1093/jac/dku564
Comparison of the Accuracy and Precision of Pharmacokinetic Equations To Predict Free Meropenem Concentrations in Critically Ill Patients
Wong, G., Farkas, A., Sussman, R., Daroczi, G., Hope, W. W., Lipman, J., & Roberts, J. A. (2015). Comparison of the Accuracy and Precision of Pharmacokinetic Equations To Predict Free Meropenem Concentrations in Critically Ill Patients. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 59(3), 1411-1417. doi:10.1128/AAC.04001-14
Population Pharmacokinetics of Micafungin and Its Metabolites M1 and M5 in Children and Adolescents
Hope, W. W., Kaibara, A., Roy, M., Arrieta, A., Azie, N., Kovanda, L. L., & Benjamin, D. K. J. (2015). Population Pharmacokinetics of Micafungin and Its Metabolites M1 and M5 in Children and Adolescents. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 59(2), 905-913. doi:10.1128/AAC.03736-14
Applying Pharmacokinetic/Pharmacodynamic Principles in Critically Ill Patients: Optimizing Efficacy and Reducing Resistance Development
Abdul-Aziz, M. H., Lipman, J., Mouton, J. W., Hope, W. W., & Roberts, J. A. (2015). Applying Pharmacokinetic/Pharmacodynamic Principles in Critically Ill Patients: Optimizing Efficacy and Reducing Resistance Development. SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 36(1), 136-153. doi:10.1055/s-0034-1398490
Guidelines need controls
Raoult, D., Hope, W., & Kahlmeter, G. (2015). Guidelines need controls. CLINICAL MICROBIOLOGY AND INFECTION, 21(12), 1043-1044. doi:10.1016/j.cmi.2015.09.010
2014
First Dose in Neonates: Are Juvenile Mice, Adults and In Vitro-In Silico Data Predictive of Neonatal Pharmacokinetics of Fluconazole
Zhao, W., Le Guellec, C., Benjamin, D. K. J., Hope, W. W., Bourgeois, T., Watt, K. M., . . . Jacqz-Aigrain, E. (2014). First Dose in Neonates: Are Juvenile Mice, Adults and In Vitro-In Silico Data Predictive of Neonatal Pharmacokinetics of Fluconazole. CLINICAL PHARMACOKINETICS, 53(11), 1005-1018. doi:10.1007/s40262-014-0169-7
Population Pharmacokinetics of Teicoplanin in Children
Ramos-Martin, V., Paulus, S., Siner, S., Scott, E., Padmore, K., Newland, P., . . . Hope, W. W. (2014). Population Pharmacokinetics of Teicoplanin in Children. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 58(11), 6920-6927. doi:10.1128/AAC.03685-14
Pulmonary Penetration of Piperacillin and Tazobactam in Critically Ill Patients
Felton, T. W., McCalman, K., Malagon, I., Isalska, B., Whalley, S., Goodwin, J., . . . Hope, W. W. (2014). Pulmonary Penetration of Piperacillin and Tazobactam in Critically Ill Patients. Clinical Pharmacology & Therapeutics, 96(4), 438-448. doi:10.1038/clpt.2014.131
Gene Expression Profiles of Human Dendritic Cells Interacting with <i>Aspergillus fumigatus</i> in a Bilayer Model of the Alveolar Epithelium/Endothelium Interface
Morton, C. O., Fliesser, M., Dittrich, M., Mueller, T., Bauer, R., Kneitz, S., . . . Loeffler, J. (2014). Gene Expression Profiles of Human Dendritic Cells Interacting with <i>Aspergillus fumigatus</i> in a Bilayer Model of the Alveolar Epithelium/Endothelium Interface. PLOS ONE, 9(5). doi:10.1371/journal.pone.0098279
Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology
Ashbee, H. R., Barnes, R. A., Johnson, E. M., Richardson, M. D., Gorton, R., & Hope, W. W. (2014). Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 69(5), 1162-1176. doi:10.1093/jac/dkt508
An invertebrate model to evaluate virulence in <i>Aspergillus fumigatus</i>: The role of azole resistance
Gomez-Lopez, A., Forastiero, A., Cendejas-Bueno, E., Gregson, L., Mellado, E., Howard, S. J., . . . Cuenca-Estrella, M. (2014). An invertebrate model to evaluate virulence in <i>Aspergillus fumigatus</i>: The role of azole resistance. MEDICAL MYCOLOGY, 52(3), 311-319. doi:10.1093/mmy/myt022
Changes in the Incidence of Candidiasis in Neonatal Intensive Care Units
Aliaga, S., Clark, R. H., Laughon, M., Walsh, T. J., Hope, W. W., Benjamin, D. K., . . . Smith, P. B. (2014). Changes in the Incidence of Candidiasis in Neonatal Intensive Care Units. PEDIATRICS, 133(2), 236-242. doi:10.1542/peds.2013-0671
Efficacy of an Abbreviated Induction Regimen of Amphotericin B Deoxycholate for Cryptococcal Meningoencephalitis: 3 Days of Therapy Is Equivalent to 14 Days
Livermore, J., Howard, S. J., Sharp, A. D., Goodwin, J., Gregson, L., Felton, T., . . . Hope, W. (2014). Efficacy of an Abbreviated Induction Regimen of Amphotericin B Deoxycholate for Cryptococcal Meningoencephalitis: 3 Days of Therapy Is Equivalent to 14 Days. mBio, 5(1). doi:10.1128/mBio.00725-13
Tissue Penetration of Antifungal Agents
Felton, T., Troke, P. F., & Hope, W. W. (2014). Tissue Penetration of Antifungal Agents. CLINICAL MICROBIOLOGY REVIEWS, 27(1), 68-88. doi:10.1128/CMR.00046-13
ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi
Chowdhary, A., Meis, J. F., Guarro, J., de Hoog, G. S., Kathuria, S., Arendrup, M. C., . . . Cuenca-Estrella, M. (2014). ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. CLINICAL MICROBIOLOGY AND INFECTION, 20, 47-75. doi:10.1111/1469-0691.12515
ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others
Tortorano, A. M., Richardson, M., Roilides, E., van Diepeningen, A., Caira, M., Munoz, P., . . . Lass-Floerl, C. (2014). ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. CLINICAL MICROBIOLOGY AND INFECTION, 20, 27-46. doi:10.1111/1469-0691.12465
ESCMID<SUP>†</SUP> and ECMM<SUP>‡</SUP> joint clinical guidelines for the diagnosis and management of mucormycosis 2013
Cornely, O. A., Arikan-Akdagli, S., Dannaoui, E., Groll, A. H., Lagrou, K., Chakrabarti, A., . . . Petrikkos, G. (2014). ESCMID<SUP>†</SUP> and ECMM<SUP>‡</SUP> joint clinical guidelines for the diagnosis and management of mucormycosis 2013. CLINICAL MICROBIOLOGY AND INFECTION, 20, 5-26. doi:10.1111/1469-0691.12371
ESCMID<SUP>†</SUP> and ECMM<SUP>‡</SUP> joint clinical guidelines for the diagnosis and management of rare invasive yeast infections
Arendrup, M. C., Boekhout, T., Akova, M., Meis, J. F., Cornely, O. A., & Lortholary, O. (2014). ESCMID<SUP>†</SUP> and ECMM<SUP>‡</SUP> joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. CLINICAL MICROBIOLOGY AND INFECTION, 20, 76-98. doi:10.1111/1469-0691.12360
EUCAST Technical Note on Candida and micafungin, anidulafungin and fluconazole
Arendrup, M. C., Cuenca-Estrella, M., Lass-Floerl, C., & Hope, W. W. (2014). EUCAST Technical Note on Candida and micafungin, anidulafungin and fluconazole. MYCOSES, 57(6), 377-379. doi:10.1111/myc.12170
Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation
Groll, A. H., Castagnola, E., Cesaro, S., Dalle, J. -H., Engelhard, D., Hope, W., . . . Lehrnbecher, T. (2014). Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. LANCET ONCOLOGY, 15(8), E327-E340. doi:10.1016/S1470-2045(14)70017-8
How severe is antibiotic pharmacokinetic variability in critically ill patients and what can be done about it?
Felton, T. W., Hope, W. W., & Roberts, J. A. (2014). How severe is antibiotic pharmacokinetic variability in critically ill patients and what can be done about it?. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 79(4), 441-447. doi:10.1016/j.diagmicrobio.2014.04.007
Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions
Roberts, J. A., Abdul-Aziz, M. H., Lipman, J., Mouton, J. W., Vinks, A. A., Felton, T. W., . . . Kuti, J. L. (2014). Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. LANCET INFECTIOUS DISEASES, 14(6), 498-509. doi:10.1016/S1473-3099(14)70036-2
Individualization of Piperacillin Dosing for Critically Ill Patients: Dosing Software To Optimize Antimicrobial Therapy
Felton, T. W., Roberts, J. A., Lodise, T. P., Van Guilder, M., Boselli, E., Neely, M. N., & Hope, W. W. (2014). Individualization of Piperacillin Dosing for Critically Ill Patients: Dosing Software To Optimize Antimicrobial Therapy. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 58(7), 4094-4102. doi:10.1128/AAC.02664-14
2013
Impact of Bolus Dosing versus Continuous Infusion of Piperacillin and Tazobactam on the Development of Antimicrobial Resistance in <i>Pseudomonas aeruginosa</i>
Felton, T. W., Goodwin, J., O'Connor, L., Sharp, A., Gregson, L., Livermore, J., . . . Hope, W. W. (2013). Impact of Bolus Dosing versus Continuous Infusion of Piperacillin and Tazobactam on the Development of Antimicrobial Resistance in <i>Pseudomonas aeruginosa</i>. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 57(12), 5811-5819. doi:10.1128/AAC.00867-13
<i>In Vitro</i> Susceptibility of <i>Aspergillus fumigatus</i> to Isavuconazole: Correlation with Itraconazole, Voriconazole, and Posaconazole
Gregson, L., Goodwin, J., Johnson, A., McEntee, L., Moore, C. B., Richardson, M., . . . Howard, S. J. (2013). <i>In Vitro</i> Susceptibility of <i>Aspergillus fumigatus</i> to Isavuconazole: Correlation with Itraconazole, Voriconazole, and Posaconazole. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 57(11), 5778-5780. doi:10.1128/AAC.01141-13
Invasive fungal infections
Hope, W., Natarajan, P., & Goodwin, L. (2013). Invasive fungal infections. CLINICAL MEDICINE, 13(5), 507-510. doi:10.7861/clinmedicine.13-5-507
Opinion: the pharmacometrics of infectious disease.
Davies, G. R., Hope, W., & Khoo, S. (2013). Opinion: the pharmacometrics of infectious disease.. CPT: pharmacometrics & systems pharmacology, 2, e70. doi:10.1038/psp.2013.46
Opinion: The Pharmacometrics of Infectious Disease
Davies, G. R., Hope, W., & Khoo, S. (2013). Opinion: The Pharmacometrics of Infectious Disease. CPT: Pharmacometrics & Systems Pharmacology, 2(8), 1-3. doi:10.1038/psp.2013.46
Pharmacodynamics of Liposomal Amphotericin B and Flucytosine for Cryptococcal Meningoencephalitis: Safe and Effective Regimens for Immunocompromised Patients
O'Connor, L., Livermore, J., Sharp, A. D., Goodwin, J., Gregson, L., Howard, S. J., . . . Hope, W. W. (2013). Pharmacodynamics of Liposomal Amphotericin B and Flucytosine for Cryptococcal Meningoencephalitis: Safe and Effective Regimens for Immunocompromised Patients. JOURNAL OF INFECTIOUS DISEASES, 208(2), 351-361. doi:10.1093/infdis/jit164
Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections
Lestner, J., & Hope, W. W. (2013). Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 9(7), 911-926. doi:10.1517/17425255.2013.794785
Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective
Lestner, J. M., Smith, P. B., Cohen-Wolkowiez, M., Benjamin, D. K. J., & Hope, W. W. (2013). Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 75(6), 1381-1395. doi:10.1111/bcp.12025
Pharmacokinetics and Pharmacodynamics of Fluconazole for Cryptococcal Meningoencephalitis: Implications for Antifungal Therapy and <i>In Vitro</i> Susceptibility Breakpoints
Sudan, A., Livermore, J., Howard, S. J., Al-Nakeeb, Z., Sharp, A., Goodwin, J., . . . Hope, W. W. (2013). Pharmacokinetics and Pharmacodynamics of Fluconazole for Cryptococcal Meningoencephalitis: Implications for Antifungal Therapy and <i>In Vitro</i> Susceptibility Breakpoints. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 57(6), 2793-2800. doi:10.1128/AAC.00216-13
Software for Dosage Individualization of Voriconazole for Immunocompromised Patients
Hope, W. W., VanGuilder, M., Donnelly, J. P., Blijlevens, N. M. A., Bruggemann, R. J. M., Jelliffe, R. W., & Neely, M. N. (2013). Software for Dosage Individualization of Voriconazole for Immunocompromised Patients. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 57(4), 1888-1894. doi:10.1128/AAC.02025-12
Breakpoints for antifungal agents: An update from EUCAST focussing on echinocandins against <i>Candida</i> spp. and triazoles against <i>Aspergillus</i> spp.
Arendrup, M. C., Cuenca-Estrella, M., Lass-Floerl, C., & Hope, W. W. (2013). Breakpoints for antifungal agents: An update from EUCAST focussing on echinocandins against <i>Candida</i> spp. and triazoles against <i>Aspergillus</i> spp.. DRUG RESISTANCE UPDATES, 16(6), 81-95. doi:10.1016/j.drup.2014.01.001
EUCAST Technical Note on Voriconazole and Aspergillus spp.
Hope, W. W., Cuenca-Estrella, M., Lass-Floerl, C., & Arendrup, M. C. (2013). EUCAST Technical Note on Voriconazole and Aspergillus spp.. CLINICAL MICROBIOLOGY AND INFECTION, 19(6), E278-E280. doi:10.1111/1469-0691.12148
Pharmacokinetics and Pharmacodynamics of Anidulafungin for Experimental <i>Candida</i> Endophthalmitis: Insights into the Utility of Echinocandins for Treatment of a Potentially Sight-Threatening Infection
Livermore, J. L., Felton, T. W., Abbott, J., Sharp, A., Goodwin, J., Gregson, L., . . . Hope, W. W. (2013). Pharmacokinetics and Pharmacodynamics of Anidulafungin for Experimental <i>Candida</i> Endophthalmitis: Insights into the Utility of Echinocandins for Treatment of a Potentially Sight-Threatening Infection. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 57(1), 281-288. doi:10.1128/AAC.01387-12
The pharmacometrics of infectious diseases
Davies, G. R., Khoo, S. H., & Hope, W. (2013). The pharmacometrics of infectious diseases. CPT: Pharmacometrics and systems pharmacology, 2, e70. Retrieved from cpt:%20pharmacomet.%20syst.%20pharmacol.%202:%20e70;%20doi:10.1038/psp.2013.46
2012
Optimizing Micafungin Dosing in Children
Zhao, W., Hope, W. W., Manzoni, P., & Jacqz-Aigrain, E. (2012). Optimizing Micafungin Dosing in Children. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 31(11), 1211-1212. doi:10.1097/INF.0b013e3182624bac
Combination of Voriconazole and Anidulafungin for Treatment of Triazole-Resistant <i>Aspergillus fumigatus</i> in an <i>In Vitro</i> Model of Invasive Pulmonary Aspergillosis
Jeans, A. R., Howard, S. J., Al-Nakeeb, Z., Goodwin, J., Gregson, L., Warn, P. A., & Hope, W. W. (2012). Combination of Voriconazole and Anidulafungin for Treatment of Triazole-Resistant <i>Aspergillus fumigatus</i> in an <i>In Vitro</i> Model of Invasive Pulmonary Aspergillosis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(10), 5180-5185. doi:10.1128/AAC.01111-12
Isolation of <i>Aspergillus</i> species from the airway of lung transplant recipients is associated with excess mortality
Felton, T. W., Roberts, S. A., Isalska, B., Brennan, S., Philips, A., Whiteside, S., . . . Hope, W. W. (2012). Isolation of <i>Aspergillus</i> species from the airway of lung transplant recipients is associated with excess mortality. JOURNAL OF INFECTION, 65(4), 350-356. doi:10.1016/j.jinf.2012.07.008
Population Pharmacokinetics of Conventional and Intermittent Dosing of Liposomal Amphotericin B in Adults: a First Critical Step for Rational Design of Innovative Regimens
Hope, W. W., Goodwin, J., Felton, T. W., Ellis, M., & Stevens, D. A. (2012). Population Pharmacokinetics of Conventional and Intermittent Dosing of Liposomal Amphotericin B in Adults: a First Critical Step for Rational Design of Innovative Regimens. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(10), 5303-5308. doi:10.1128/AAC.00933-12
Comparison of Dimethyl Sulfoxide and Water as Solvents for Echinocandin Susceptibility Testing by the EUCAST Methodology (vol 50, pg 2509, 2012)
Alastruey-Izquierdo, A., Gomez-Lopez, A., Arendrup, M. C., Lass-Florl, C., Hope, W. W., Perlin, D. S., . . . Cuenca-Estrella, M. (2012). Comparison of Dimethyl Sulfoxide and Water as Solvents for Echinocandin Susceptibility Testing by the EUCAST Methodology (vol 50, pg 2509, 2012). JOURNAL OF CLINICAL MICROBIOLOGY, 50(9), 3149. doi:10.1128/JCM.01843-12
Pharmacodynamics of Itraconazole against <i>Aspergillus fumigatus</i> in an <i>In</i> <i>Vitro</i> Model of the Human Alveolus: Perspectives on the Treatment of Triazole-Resistant Infection and Utility of Airway Administration
Al-Nakeeb, Z., Sudan, A., Jeans, A. R., Gregson, L., Goodwin, J., Warn, P. A., . . . Hope, W. W. (2012). Pharmacodynamics of Itraconazole against <i>Aspergillus fumigatus</i> in an <i>In</i> <i>Vitro</i> Model of the Human Alveolus: Perspectives on the Treatment of Triazole-Resistant Infection and Utility of Airway Administration. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(8), 4146-4153. doi:10.1128/AAC.00141-12
Pharmacodynamics of Voriconazole in a Dynamic In Vitro Model of Invasive Pulmonary Aspergillosis: Implications for In Vitro Susceptibility Breakpoints
Jeans, A. R., Howard, S. J., Al-Nakeeb, Z., Goodwin, J., Gregson, L., Majithiya, J. B., . . . Hope, W. W. (2012). Pharmacodynamics of Voriconazole in a Dynamic In Vitro Model of Invasive Pulmonary Aspergillosis: Implications for In Vitro Susceptibility Breakpoints. JOURNAL OF INFECTIOUS DISEASES, 206(3), 442-452. doi:10.1093/infdis/jis372
Population Pharmacokinetics of Extended-Infusion Piperacillin-Tazobactam in Hospitalized Patients with Nosocomial Infections
Felton, T. W., Hope, W. W., Lomaestro, B. M., Butterfield, J. M., Kwa, A. L., Drusano, G. L., & Lodise, T. P. (2012). Population Pharmacokinetics of Extended-Infusion Piperacillin-Tazobactam in Hospitalized Patients with Nosocomial Infections. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(8), 4087-4094. doi:10.1128/AAC.00521-12
Comparison of dimethyl sulfoxide and water as solvents for echinocandin susceptibility testing by the EUCAST methodology.
Alastruey-Izquierdo, A., Gómez-López, A., Arendrup, M. C., Lass-Florl, C., Hope, W. W., Perlin, D. S., . . . Cuenca-Estrella, M. (2012). Comparison of dimethyl sulfoxide and water as solvents for echinocandin susceptibility testing by the EUCAST methodology.. Journal of clinical microbiology, 50(7), 2509-2512. doi:10.1128/jcm.00791-12
Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections
Livermore, J., & Hope, W. (2012). Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 8(6), 759-765. doi:10.1517/17425255.2012.683859
Differential <i>In Vivo</i> Activities of Anidulafungin, Caspofungin, and Micafungin against <i>Candida glabrata</i> Isolates with and without <i>FKS</i> Resistance Mutations
Arendrup, M. C., Perlin, D. S., Jensen, R. H., Howard, S. J., Goodwin, J., & Hope, W. (2012). Differential <i>In Vivo</i> Activities of Anidulafungin, Caspofungin, and Micafungin against <i>Candida glabrata</i> Isolates with and without <i>FKS</i> Resistance Mutations. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(5), 2435-2442. doi:10.1128/AAC.06369-11
Clinical utility of micafungin: pharmacokinetics, dosing, use in special populations and drug interactions
Hope, W. W., Howard, S. J., & Felton, T. W. (2012). Clinical utility of micafungin: pharmacokinetics, dosing, use in special populations and drug interactions. MYCOSES, 55, 33-38. doi:10.1111/j.1439-0507.2011.02114.x
Posaconazole: The Case for Therapeutic Drug Monitoring
Howard, S. J., Felton, T. W., Gomez-Lopez, A., & Hope, W. W. (2012). Posaconazole: The Case for Therapeutic Drug Monitoring. THERAPEUTIC DRUG MONITORING, 34(1), 72-76. doi:10.1097/FTD.0b013e31823cdeac
Anidulafungin for Neonatal Hematogenous <i>Candida</i> Meningoencephalitis: Identification of Candidate Regimens for Humans Using a Translational Pharmacological Approach
Warn, P. A., Livermore, J., Howard, S., Felton, T. W., Sharp, A., Gregson, L., . . . Hope, W. W. (2012). Anidulafungin for Neonatal Hematogenous <i>Candida</i> Meningoencephalitis: Identification of Candidate Regimens for Humans Using a Translational Pharmacological Approach. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(2), 708-714. doi:10.1128/AAC.05826-11
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT)
Ullmann, A. J., Akova, M., Herbrecht, R., Viscoli, C., Arendrup, M. C., Arikan-Akdagli, S., . . . Cuenca-Estrella, M. (2012). ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). CLINICAL MICROBIOLOGY AND INFECTION, 18, 53-67. doi:10.1111/1469-0691.12041
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases
Ullmann, A. J., Cornely, O. A., Donnelly, J. P., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., . . . Cuenca-Estrella, M. (2012). ESCMID* guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases. CLINICAL MICROBIOLOGY AND INFECTION, 18, 1-8. doi:10.1111/1469-0691.12037
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures
Cuenca-Estrella, M., Verweij, P. E., Arendrup, M. C., Arikan-Akdagli, S., Bille, J., Donnelly, J. P., . . . Ullmann, A. J. (2012). ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. CLINICAL MICROBIOLOGY AND INFECTION, 18, 9-18. doi:10.1111/1469-0691.12038
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients
Cornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., . . . Ullmann, A. J. (2012). ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. CLINICAL MICROBIOLOGY AND INFECTION, 18, 19-37. doi:10.1111/1469-0691.12039
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS
Lortholary, O., Petrikkos, G., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., Bassetti, M., . . . Ullmann, A. J. (2012). ESCMID* guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS. CLINICAL MICROBIOLOGY AND INFECTION, 18, 68-77. doi:10.1111/1469-0691.12042
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp.
Hope, W. W., Castagnola, E., Groll, A. H., Roilides, E., Akova, M., Arendrup, M. C., . . . Ullmann, A. J. (2012). ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp.. CLINICAL MICROBIOLOGY AND INFECTION, 18, 38-52. doi:10.1111/1469-0691.12040
EUCAST Technical Note on Aspergillus and amphotericin B, itraconazole, and posaconazole
Arendrup, M. C., Cuenca-Estrella, M., Lass-Floel, C., & Hope, W. W. (2012). EUCAST Technical Note on Aspergillus and amphotericin B, itraconazole, and posaconazole. CLINICAL MICROBIOLOGY AND INFECTION, 18(7), E248-E250. doi:10.1111/j.1469-0691.2012.03890.x
EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST)
Arendrup, M. C., Cuenca-Estrella, M., Lass-Floerl, C., & Hope, W. (2012). EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). CLINICAL MICROBIOLOGY AND INFECTION, 18(7), E246-E247. doi:10.1111/j.1469-0691.2012.03880.x
In vitro model of invasive pulmonary aspergillosis in the human alveolus.
Gregson, L., Hope, W. W., & Howard, S. J. (2012). In vitro model of invasive pulmonary aspergillosis in the human alveolus.. Methods in molecular biology (Clifton, N.J.), 845, 361-367. doi:10.1007/978-1-61779-539-8_24
Pharmacokinetics and Pharmacodynamics of Anidulafungin for Experimental Candida Endophthalmitis: Insights into the Utility of Echinocandins for Treatment of a Potentially Sight-Threatening Infection.
Livermore, J. L., Felton, T. W., Abbott, J., Sharp, A., Goodwin, J., Gregson, L., . . . Hope, W. W. (2012). Pharmacokinetics and Pharmacodynamics of Anidulafungin for Experimental Candida Endophthalmitis: Insights into the Utility of Echinocandins for Treatment of a Potentially Sight-Threatening Infection.. Antimicrob Agents Chemother..
Population Pharmacokinetics of Voriconazole in Adults
Hope, W. W. (2012). Population Pharmacokinetics of Voriconazole in Adults. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(1), 526-531. doi:10.1128/AAC.00702-11
2011
Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients (vol 55, pg 4782, 2011)
Troke, P. F., Hockey, H. P., & Hope, W. W. (2011). Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients (vol 55, pg 4782, 2011). ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(11), 5415. doi:10.1128/AAC.05771-11
Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients
Troke, P. F., Hockey, H. P., & Hope, W. W. (2011). Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(10), 4782-4788. doi:10.1128/AAC.01083-10
Pharmacodynamics of Echinocandins against <i>Candida glabrata</i>: Requirement for Dosage Escalation To Achieve Maximal Antifungal Activity in Neutropenic Hosts
Howard, S. J., Livermore, J., Sharp, A., Goodwin, J., Gregson, L., Alastruey-Izquierdo, A., . . . Hope, W. W. (2011). Pharmacodynamics of Echinocandins against <i>Candida glabrata</i>: Requirement for Dosage Escalation To Achieve Maximal Antifungal Activity in Neutropenic Hosts. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(10), 4880-4887. doi:10.1128/AAC.00621-11
Can We Achieve Clinical Breakpoints for the Triazoles in Aspergillosis?
Rodriguez-Tudela, J. L., Hope, W., Cuenca-Estrella, M., Donnelly, J. P., Lass-Flörl, C., & Arendrup, M. C. (2011). Can We Achieve Clinical Breakpoints for the Triazoles in Aspergillosis?. Current Fungal Infection Reports, 5(3), 128-134. doi:10.1007/s12281-011-0058-6
Disseminated Candidiasis Caused by <i>Candida albicans</i> with Amino Acid Substitutions in Fks1 at Position Ser645 Cannot Be Successfully Treated with Micafungin
Slater, J. L., Howard, S. J., Sharp, A., Goodwin, J., Gregson, L. M., Alastruey-Izquierdo, A., . . . Hope, W. W. (2011). Disseminated Candidiasis Caused by <i>Candida albicans</i> with Amino Acid Substitutions in Fks1 at Position Ser645 Cannot Be Successfully Treated with Micafungin. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(7), 3075-3083. doi:10.1128/AAC.01686-10
Pharmacokinetics and Pharmacodynamics of Posaconazole for Invasive Pulmonary Aspergillosis: Clinical Implications for Antifungal Therapy
Howard, S. J., Lestner, J. M., Sharp, A., Gregson, L., Goodwin, J., Slater, J., . . . Hope, W. W. (2011). Pharmacokinetics and Pharmacodynamics of Posaconazole for Invasive Pulmonary Aspergillosis: Clinical Implications for Antifungal Therapy. JOURNAL OF INFECTIOUS DISEASES, 203(9), 1324-1332. doi:10.1093/infdis/jir023
Safety and Pharmacokinetics of Multiple-Dose Anidulafungin in Infants and Neonates
Cohen-Wolkowiez, M., Benjamin, D. K. J., Piper, L., Cheifetz, I. M., Moran, C., Liu, P., . . . Smith, P. B. (2011). Safety and Pharmacokinetics of Multiple-Dose Anidulafungin in Infants and Neonates. CLINICAL PHARMACOLOGY & THERAPEUTICS, 89(5), 702-707. doi:10.1038/clpt.2011.26
EUCAST Technical note on Amphotericin B
Lass-Floerl, C., Arendrup, M. C., Rodriguez-Tudela, J. -L., Cuenca-Estrella, M., Donnelly, P., & Hope, W. (2011). EUCAST Technical note on Amphotericin B. CLINICAL MICROBIOLOGY AND INFECTION, 17(12), E27-E29. doi:10.1111/j.1469-0691.2011.03644.x
EUCAST technical note on anidulafungin
Arendrup, M. C., Rodriguez-Tudela, J. -L., Lass-Floerl, C., Cuenca-Estrella, M., Donnelly, J. P., & Hope, W. (2011). EUCAST technical note on anidulafungin. CLINICAL MICROBIOLOGY AND INFECTION, 17(11), E18-E20. doi:10.1111/j.1469-0691.2011.03647.x
EUCAST technical note on posaconazole
Arendrup, M. C., Cuenca-Estrella, M., Donnelly, J. P., Hope, W., Lass-Floerl, C., & Rodriguez-Tudela, J. -L. (2011). EUCAST technical note on posaconazole. CLINICAL MICROBIOLOGY AND INFECTION, 17(11), E16-E17. doi:10.1111/j.1469-0691.2011.03646.x
Fluconazole Loading Dose Pharmacokinetics and Safety in Infants
Piper, L., Smith, P. B., Hornik, C. P., Cheifetz, I. M., Barrett, J. S., Moorthy, G., . . . Benjamin, D. K. J. (2011). Fluconazole Loading Dose Pharmacokinetics and Safety in Infants. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 30(5), 375-378. doi:10.1097/INF.0b013e318202cbb3
Innate immunity in human newborn infants: prematurity means more than immaturity.
Strunk, T., Currie, A., Richmond, P., Simmer, K., & Burgner, D. (2011). Innate immunity in human newborn infants: prematurity means more than immaturity.. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 24(1), 25-31. doi:10.3109/14767058.2010.482605
Optimizing management of invasive mould diseases
Agrawal, S., Hope, W., Sinko, J., & Kibbler, C. (2011). Optimizing management of invasive mould diseases. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 66, i45-i53. doi:10.1093/jac/dkq441
Robotic suturing on the FLS model possesses construct validity, is less physically demanding, and is favored by more surgeons compared with laparoscopy.
Stefanidis, D., Hope, W. W., & Scott, D. J. (2011). Robotic suturing on the FLS model possesses construct validity, is less physically demanding, and is favored by more surgeons compared with laparoscopy.. Surgical endoscopy, 25(7), 2141-2146. doi:10.1007/s00464-010-1512-1
The management of <i>Candida</i> infections in preterm neonates and the role of micafungin
Manzoni, P., Benjamin, D. K., Hope, W., Rizzollo, S., Del Sordo, P., Stronati, M., . . . Farina, D. (2011). The management of <i>Candida</i> infections in preterm neonates and the role of micafungin. JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 24, 25-28. doi:10.3109/14767058.2011.604929
2010
Efficacy and Safety of Posaconazole for Chronic Pulmonary Aspergillosis
Felton, T. W., Baxter, C., Moore, C. B., Roberts, S. A., Hope, W. W., & Denning, D. W. (2010). Efficacy and Safety of Posaconazole for Chronic Pulmonary Aspergillosis. CLINICAL INFECTIOUS DISEASES, 51(12), 1383-1391. doi:10.1086/657306
The Initial 96 Hours of Invasive Pulmonary Aspergillosis: Histopathology, Comparative Kinetics of Galactomannan and (1→3)-β-D-Glucan, and Consequences of Delayed Antifungal Therapy
Hope, W. W., Petraitis, V., Petraitiene, R., Aghamolla, T., Bacher, J., & Walsh, T. J. (2010). The Initial 96 Hours of Invasive Pulmonary Aspergillosis: Histopathology, Comparative Kinetics of Galactomannan and (1→3)-β-D-Glucan, and Consequences of Delayed Antifungal Therapy. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(11), 4879-4886. doi:10.1128/AAC.00673-10
Pharmacokinetics and Pharmacodynamics of Amphotericin B Deoxycholate, Liposomal Amphotericin B, and Amphotericin B Lipid Complex in an <i>In Vitro</i> Model of Invasive Pulmonary Aspergillosis
Lestner, J. M., Howard, S. J., Goodwin, J., Gregson, L., Majithiya, J., Walsh, T. J., . . . Hope, W. W. (2010). Pharmacokinetics and Pharmacodynamics of Amphotericin B Deoxycholate, Liposomal Amphotericin B, and Amphotericin B Lipid Complex in an <i>In Vitro</i> Model of Invasive Pulmonary Aspergillosis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(8), 3432-3441. doi:10.1128/AAC.01586-09
Population Pharmacokinetics of Micafungin in Neonates and Young Infants
Hope, W. W., Smith, P. B., Arrieta, A., Buell, D. N., Roy, M., Kaibara, A., . . . Benjamin, D. K. J. (2010). Population Pharmacokinetics of Micafungin in Neonates and Young Infants. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(6), 2633-2637. doi:10.1128/AAC.01679-09
Therapeutic drug monitoring of β-lactams for critically ill patients: unwarranted or essential?
Roberts, J. A., Hope, W. W., & Lipman, J. (2010). Therapeutic drug monitoring of β-lactams for critically ill patients: unwarranted or essential?. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 35(5), 419-420. doi:10.1016/j.ijantimicag.2010.01.022
Therapy for fungal diseases: opportunities and priorities
Denning, D. W., & Hope, W. W. (2010). Therapy for fungal diseases: opportunities and priorities. TRENDS IN MICROBIOLOGY, 18(5), 195-204. doi:10.1016/j.tim.2010.02.004
Antifungal Therapeutic Drug Monitoring for Invasive Aspergillosis
Howard, S. J., & Hope, W. W. (2010). Antifungal Therapeutic Drug Monitoring for Invasive Aspergillosis. In ASPERGILLOSIS: FROM DIAGNOSIS TO PREVENTION (pp. 217-228). doi:10.1007/978-90-481-2408-4_14
Echinocandins
Perlin, D. S., & Hope, W. W. (2010). Echinocandins. In ASPERGILLOSIS: FROM DIAGNOSIS TO PREVENTION (pp. 263-279). doi:10.1007/978-90-481-2408-4_16
Safety and Pharmacokinetics of Repeat-Dose Micafungin in Young Infants
Benjamin, D. K. J., Smith, P. B., Arrieta, A., Castro, L., Sanchez, P. J., Kaufman, D., . . . Walsh, T. J. (2010). Safety and Pharmacokinetics of Repeat-Dose Micafungin in Young Infants. CLINICAL PHARMACOLOGY & THERAPEUTICS, 87(1), 93-99. doi:10.1038/clpt.2009.200
2009
Aspergillus
Malcolm, D., Richardson, K. B., & Hope, W. (2009). Aspergillus. In Clinical Mycology (pp. 271-296). Elsevier. doi:10.1016/b978-1-4160-5680-5.00011-6
Toxicodynamics of Itraconazole: Implications for Therapeutic Drug Monitoring
Lestner, J. M., Roberts, S. A., Moore, C. B., Howard, S. J., Denning, D. W., & Hope, W. W. (2009). Toxicodynamics of Itraconazole: Implications for Therapeutic Drug Monitoring. CLINICAL INFECTIOUS DISEASES, 49(6), 928-930. doi:10.1086/605499
Invasion of the alveolar-capillary barrier by Aspergillus spp.: therapeutic and diagnostic implications for immunocompromised patients with invasive pulmonary aspergillosis
Hope, W. W. (2009). Invasion of the alveolar-capillary barrier by Aspergillus spp.: therapeutic and diagnostic implications for immunocompromised patients with invasive pulmonary aspergillosis. MEDICAL MYCOLOGY, 47, S291-S298. doi:10.1080/13693780802510232
Pharmacokinetics and Pharmacodynamics of a Novel Triazole, Isavuconazole: Mathematical Modeling, Importance of Tissue Concentrations, and Impact of Immune Status on Antifungal Effect
Warn, P. A., Sharp, A., Parmar, A., Majithiya, J., Denning, D. W., & Hope, W. W. (2009). Pharmacokinetics and Pharmacodynamics of a Novel Triazole, Isavuconazole: Mathematical Modeling, Importance of Tissue Concentrations, and Impact of Immune Status on Antifungal Effect. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 53(8), 3453-3461. doi:10.1128/AAC.01601-08
<i>Rational Testing</i> Assessing candiduria in a critically ill patient
Hope, W. W. (2009). <i>Rational Testing</i> Assessing candiduria in a critically ill patient. BRITISH MEDICAL JOURNAL, 338. doi:10.1136/bmj.b2289
Combination Therapy in Treatment of Experimental Pulmonary Aspergillosis: In Vitro and In Vivo Correlations of the Concentration- and Dose-Dependent Interactions between Anidulafungin and Voriconazole by Bliss Independence Drug Interaction Analysis
Petraitis, V., Petraitiene, R., Hope, W. W., Meletiadis, J., Mickiene, D., Hughes, J. E., . . . Walsh, T. J. (2009). Combination Therapy in Treatment of Experimental Pulmonary Aspergillosis: In Vitro and In Vivo Correlations of the Concentration- and Dose-Dependent Interactions between Anidulafungin and Voriconazole by Bliss Independence Drug Interaction Analysis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 53(6), 2382-2391. doi:10.1128/AAC.00329-09
Aspergillus
Malcolm, D., Richardson, K. B., & Hope, W. (2009). Aspergillus. In Clinical Mycology with CD-ROM (pp. 271-296). doi:10.1016/B978-1-4160-5680-5/00011-6
Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside
Hope, W. W., & Drusano, G. L. (2009). Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside. CLINICAL MICROBIOLOGY AND INFECTION, 15(7), 602-612. doi:10.1111/j.1469-0691.2009.02913.x
Pharmacokinetics of an Elevated Dosage of Micafungin in Premature Neonates
Smith, P. B., Walsh, T. J., Hope, W., Arrieta, A., Takada, A., Kovanda, L. L., . . . Benjamin, D. K. J. (2009). Pharmacokinetics of an Elevated Dosage of Micafungin in Premature Neonates. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 28(5), 412-415. doi:10.1097/INF.0b013e3181910e2d
2008
Therapeutic drug monitoring for triazoles
Hope, W. W., Billaud, E. M., Lestner, J., & Denning, D. W. (2008). Therapeutic drug monitoring for triazoles. CURRENT OPINION IN INFECTIOUS DISEASES, 21(6), 580-586. doi:10.1097/QCO.0b013e3283184611
Cerebrospinal Fluid and Plasma (1→3)-β-D-Glucan as Surrogate Markers for Detection and Monitoring of Therapeutic Response in Experimental Hematogenous <i>Candida</i> Meningoencephalitis
Petraitiene, R., Petraitis, V., Hope, W. W., Mickiene, D., Kelaher, A. M., Murray, H. A., . . . Walsh, T. J. (2008). Cerebrospinal Fluid and Plasma (1→3)-β-D-Glucan as Surrogate Markers for Detection and Monitoring of Therapeutic Response in Experimental Hematogenous <i>Candida</i> Meningoencephalitis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 52(11), 4121-4129. doi:10.1128/AAC.00674-08
Interactions of <i>Aspergillus</i> with the Mucosa
Hope, W. W., & Filler, S. G. (n.d.). Interactions of <i>Aspergillus</i> with the Mucosa. In <i>Aspergillus fumigatus</i> and Aspergillosis (pp. 239-245). ASM Press. doi:10.1128/9781555815523.ch19
Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., . . . Bennett, J. E. (2008). Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. CLINICAL INFECTIOUS DISEASES, 46(12), 1813-1821. doi:10.1086/588660
Experimental Design Considerations in Pharmacokinetic Studies
Hope, W. W., Petraitis, V., & Walsh, T. J. (2008). Experimental Design Considerations in Pharmacokinetic Studies. In Unknown Book (pp. 1059-1068). Wiley. doi:10.1002/9780470249031.ch31
The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous <i>Candida</i> meningoencephalitis:: Implications for echinocandin therapy in neonates
Hope, W. W., Mickiene, D., Petraitis, V., Petraitiene, R., Kelaher, A. M., Hughes, J. E., . . . Walsh, T. J. (2008). The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous <i>Candida</i> meningoencephalitis:: Implications for echinocandin therapy in neonates. JOURNAL OF INFECTIOUS DISEASES, 197(1), 163-171. doi:10.1086/524063
2007
Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosing
Hope, W. W., Warn, P. A., Sharp, A., Reed, P., Keevil, B., Louie, A., . . . Drusano, G. L. (2007). Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosing. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 51(10), 3760-3762. doi:10.1128/AAC.00488-07
Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing
Hope, W. W., Seibel, N. L., Schwartz, C. L., Arrieta, A., Flynn, P., Shad, A., . . . Walsh, T. J. (2007). Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 51(10), 3714-3719. doi:10.1128/AAC.00398-07
The pharmacology and clinical use of caspofungin
Hope, W. W., Shoham, S., & Walsh, T. J. (2007). The pharmacology and clinical use of caspofungin. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 3(2), 263-274. doi:10.1517/17425255.3.2.263
Pathogenesis of <i>Aspergillus fumigatus</i> and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis:: Implications for antifungal therapy
Hope, W. W., Kruhlak, M. J., Lyman, C. A., Petraitiene, R., Petraitis, V., Francesconi, A., . . . Walsh, T. J. (2007). Pathogenesis of <i>Aspergillus fumigatus</i> and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis:: Implications for antifungal therapy. JOURNAL OF INFECTIOUS DISEASES, 195(3), 455-466. doi:10.1086/510535
Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis
Hope, W. W., Drusano, G. L., Moore, C. B., Sharp, A., Louie, A., Walsh, T. J., . . . Warn, P. A. (2007). Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 51(1), 285-295. doi:10.1128/AAC.00601-06
Galactomannan antigen detection in the diagnosis of invasive aspergillosis
Verdaguer, V., Walsh, T. J., Hope, W., & Cortez, K. J. (2007). Galactomannan antigen detection in the diagnosis of invasive aspergillosis. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 7(1), 21-32. doi:10.1586/14737159.7.1.21
2006
Derivation of an in vivo drug exposure breakpoint for flucytosine against <i>Candida albicans</i> and impact of the MIC, growth rate, and resistance genotype on the antifungal effect
Hope, W. W., Warn, P. A., Sharp, A., Howard, S., Kasai, M., Louie, A., . . . Denning, D. W. (2006). Derivation of an in vivo drug exposure breakpoint for flucytosine against <i>Candida albicans</i> and impact of the MIC, growth rate, and resistance genotype on the antifungal effect. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 50(11), 3680-3688. doi:10.1128/AAC.00369-06
Clinical research in the lay press: Irresponsible journalism raises a huge dose of doubt
Anaissie, E. J., Segal, B. H., Graybill, J. R., Arndt, C., Perfect, J. R., Kleinberg, M., . . . Zaoutis, T. (2006). Clinical research in the lay press: Irresponsible journalism raises a huge dose of doubt. CLINICAL INFECTIOUS DISEASES, 43(8), 1031-1039. doi:10.1086/509116
Characterization and comparison of galactomannan enzyme immunoassay and quantitative real-time PCR assay for detection of <i>Aspergillus fumigatus</i> in bronchoalveolar lavage fluid from experimental invasive pulmonary aspergillosis
Francesconi, A., Kasai, M., Petraitiene, R., Petraitis, V., Kelaher, A. M., Schaufele, R., . . . Walsh, T. J. (2006). Characterization and comparison of galactomannan enzyme immunoassay and quantitative real-time PCR assay for detection of <i>Aspergillus fumigatus</i> in bronchoalveolar lavage fluid from experimental invasive pulmonary aspergillosis. JOURNAL OF CLINICAL MICROBIOLOGY, 44(7), 2475-2480. doi:10.1128/JCM.02693-05
2005
Laboratory diagnosis of invasive aspergillosis
Hope, W. W., Walsh, T. J., & Denning, D. W. (2005). Laboratory diagnosis of invasive aspergillosis. LANCET INFECTIOUS DISEASES, 5(10), 609-622. doi:10.1016/S1473-3099(05)70238-3
Surface response modeling to examine the combination of amphotericin B deoxycholate and 5-fluorocytosine for treatment of invasive candidiasis
Hope, W. W., Warn, P. A., Sharp, A., Reed, P., Keevil, B., Louie, A., . . . Drusano, G. L. (2005). Surface response modeling to examine the combination of amphotericin B deoxycholate and 5-fluorocytosine for treatment of invasive candidiasis. JOURNAL OF INFECTIOUS DISEASES, 192(4), 673-680. doi:10.1086/432069
The invasive and saprophytic syndromes due to <i>Aspergillus</i> spp.
Hope, W. W., Walsh, T. J., & Denning, D. W. (2005). The invasive and saprophytic syndromes due to <i>Aspergillus</i> spp.. MEDICAL MYCOLOGY, 43, S207-S238. doi:10.1080/13693780400025179
2004
Molecular mechanisms of primary resistance to flucytosine in <i>Candida albicans</i>
Hope, W. W., Tabernero, L., Denning, D. W., & Anderson, M. J. (2004). Molecular mechanisms of primary resistance to flucytosine in <i>Candida albicans</i>. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 48(11), 4377-4386. doi:10.1128/AAC.48.11.4377-4386.2004
Invasive pulmonary aspergillosis with spontaneous resolution and the diagnostic utility of PCR from tissue specimens
Hope, W. W., Padwell, A., Guiver, M., & Denning, D. W. (2004). Invasive pulmonary aspergillosis with spontaneous resolution and the diagnostic utility of PCR from tissue specimens. JOURNAL OF INFECTION, 49(2), 136-140. doi:10.1016/j.jinf.2004.02.008
Optimising antifungal therapy for individual patients
Hope, W. W., & Denning, D. W. (2004). Optimising antifungal therapy for individual patients. INTERNAL MEDICINE JOURNAL, 34(4), 147-149. doi:10.1111/j.1444-0903.2004.00569.x
A PCR method for the identification of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) from screening swabs
Hope, W. W., Morton, A. P., Looke, D. F. M., Schooneveldt, J. M., & Nimmo, G. R. (2004). A PCR method for the identification of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) from screening swabs. PATHOLOGY, 36(3), 265-268. doi:10.1080/00313020410001692530
Invasive aspergillosis: current and future challenges in diagnosis and therapy
Hope, W. W., & Denning, D. W. (2004). Invasive aspergillosis: current and future challenges in diagnosis and therapy. CLINICAL MICROBIOLOGY AND INFECTION, 10(1), 2-4. doi:10.1111/j.1469-0691.2004.00809.x
2003
Sequential infection with <i>Nocardia farcinica</i> and <i>Cryptococcus neoformans</i> var. <i>gattii</i> in an immunocompetent host
Hope, W., & Looke, D. (2003). Sequential infection with <i>Nocardia farcinica</i> and <i>Cryptococcus neoformans</i> var. <i>gattii</i> in an immunocompetent host. JOURNAL OF INFECTION, 47(3), 256-259. doi:10.1016/S0163-4453(03)00083-5
2002
A case of bacteremic pyelonephritis due to Pasteurella multocida subsp. multocida
Hope, W. W., Flohr, G., & Nimmo, G. R. (2002). A case of bacteremic pyelonephritis due to Pasteurella multocida subsp. multocida. Clinical Microbiology Newsletter, 24(18), 140-141. doi:10.1016/s0196-4399(02)80036-8
Urine D-arabinitol/L-arabinitol ratio in diagnosing <i>Candida</i> infection in patients with haematological malignancy and HIV infection
Eisen, D. P., Bartley, P. B., Hope, W., Sigmundsdottir, G., Pehrson, C., Larsson, L., & Christensson, B. (2002). Urine D-arabinitol/L-arabinitol ratio in diagnosing <i>Candida</i> infection in patients with haematological malignancy and HIV infection. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 42(1), 39-42. doi:10.1016/S0732-8893(01)00310-8
Increase in prevalence of nosocomial non-<i>Candida albicans</i> candidaemia and the association of <i>Candida krusei</i> with fluconazole use
Hope, W., Morton, A., & Eisen, D. P. (2002). Increase in prevalence of nosocomial non-<i>Candida albicans</i> candidaemia and the association of <i>Candida krusei</i> with fluconazole use. JOURNAL OF HOSPITAL INFECTION, 50(1), 56-65. doi:10.1053/jhin.2001.1131